National Cancer Control Programme

Cancer Incidence Data Sri Lanka 2010







Table 13: Cancer cases by ethnicity, sex and sub-site, 2010

ICD O Code and Site	All		Sinhala		Tamil		Muslim		Other		Ur
	Male	Female	Male	Female	Male	Female	Male	Female	Male	Female	Male
C00 Lip	64	26	55	12	4	9	5	4	0	0	0
C01 Base of tongue	117	13	97	11	11	1	2	0	6	1	1
specified parts of tongue	373	70	327	52	28	12	7	3	8	3	3
	115	51	92	35	15	10	4	5	3	1	1
	101	16	86	13	7	2	3	1	3	0	2
cified parts of mouth	104	37	85	25	16	9	0	3	3	0	0
	515	212	417	123	63	49	15	32	13	3	7
pecified major salivary	32	27	29	25	2	2	1	0	0	0	0
	19	13	17	9	0	4	2	0	0	0	0
	131	23	115	17	8	3	4	0	4	1	0
	86	6	67	4	13	0	6	1	0	0	0
	28	12	25	10	1	1	1	1	1	0	0
	169	18	136	10	25	5	3	2	4	1	1
s in lip, oral cavity	26	22	21	12	3	9	1	0	0	1	1
	59	28	46	19	10	6	2	2	1	0	0
	574	496	471	362	63	106	22	18	15	6	3
	226	97	177	59	32	22	11	11	6	3	0
	22	19	20	16	0	2	1	1	1	0	0
	221	222	191	188	14	13	11	14	2	6	3
	30	46	28	37	2	3	0	5	0	1	0
	316	248	273	214	19	19	13	11	10	4	1
ts	28	22	23	17	2	1	2	2	1	1	0
	132	38	115	28	7	3	6	3	4	4	0
iliary tract	10	24	7	18	1	2	1	3	0	1	1
	32	24	24	13	4	9	3	1	1	0	0
ians	46	56	39	45	5	8	2	3	0	0	0
	13	9	11	7	1	0	1	2	0	0	0
	23	8	18	6	5	0	0	2	0	0	0
	27	14	19	10	5	3	2	1	0	0	1
C34 Bronchus and lung	384	36	323	27	34	8	15	1	9	0	3
C37 Thymus	5	0	5	0	0	0	0	0	0	0	0
C38 Heart, mediastinum and pleura	801	209	638	160	83	25	59	16	15	0	0
C40 Bones, joints and articular limbs	12	9	11	7	1						
	13										

Cancer Incidence Data
Sri Lanka 2010

National Cancer Control Programme
555, Elvitigala Mawatha
Colombo 5
Sri Lanka

ISBN: 978-955-0505-84-5

National Cancer Control Programme-2016

12th Publication

Printed by: Gunarathne Offset (Pvt) Ltd.

Contributors

Data Collection

Dr. Suraj Perera
Dr. K.G. Nirmala Jayanthi
Dr. Asanga Hemaratne
Dr. Pushpika Samarakoon
Dr. Ruwanmalie Liyanagama
Dr. Kamal Seneviratne
Dr. L.D. Ratnasiri
Sr. Chamila Peiris
Dr. J.K.V. Madhushaka
Dr. M.Y.T. Fernando
Dr. K.M.V.C. Bandara
Dr. G.D.T. Kanchana
Dr. G.K. Basnayaka
Dr. H.D. Siriwardana
Dr. O.A.R. Kularatna
Dr. J.C. Jayasingha
Dr. J.M.M.A.Jayasundara
Dr. Sachithra Samarakoon

Data Coding

Dr. K.G. Nirmala Jayanthi
Dr. Pushpika Samarakoon
Dr. Asanga Hemaratne
Dr. Ruwanmalie Liyanagama
Sr. Chamila Peiris
Dr. Shreeni Alahapperuma

Verification

Dr. Pushpika Samarakoon, Dr. K.G. Nirmala Jayanthi & Dr. Eshani Fernando

Data Entry

Ms. Nimesha Prasadi
Ms. Prabashi Gayanthika

Statistical Analysis and Report Writing

Dr. Eshani Fernando

GIS Maps

Special thanks to Dr. Chaminda Siribaddana, Medical Officer Health Informatics, Ministry of Health for GIS Maps

Support Staff

Mr. Saman Kumara Mahalekam
Ms. Thushari Dhammika
Mr. U.K. Sumanasiri
Mr. Siripala Perera
Mr. Sineth Eranga

Message from Director General of Health Services



It is with great pleasure that I send this message to the 12th edition of 'Cancer Incidence Data - Sri Lanka 2010' published by the National Cancer Control Programme of the Ministry of Health, Nutrition & Indigenous Medicine. An organized system for cancer registration commenced in 1985 in Sri Lanka with the establishment of the National Cancer Control Programme. Since the publication of the first report in 1990, twelve publications have been released on cancer incidence data up to now. I am happy to note that annual publications are recommenced from 2005.

Prevention & control of non-communicable diseases (NCD) is one of the priorities of global health agenda. World Health Organization (WHO) has identified health information as one of the major building block of health system strengthening for NCD control. Therefore the information on cancer incidence is extremely useful in planning, resource allocation, implementation and monitoring of activities related to cancer control at national and sub national level.

I would like to thank WHO country office and the International Agency for Research on Cancer (IARC) for providing technical support to further strengthen cancer registration in Sri Lanka. I highly appreciate the contributions of different stakeholders including the staff of oncology units, histopathology & haematology laboratories and Oro-Maxillo Facial (OMF) units in providing relevant data. The hard work of National Cancer Control Programme for the coordination of this activity is highly acknowledged.

Dr. Palitha Mahipala
Director General of Health Services

Message from Deputy Director General of Non Communicable Diseases



It is with great pleasure, I am sending this message to the 12th edition of 'Cancer Incidence Data - Sri Lanka 2010' published by the National Cancer Control Programme.

Cancer incidence data is one of the main outputs of the cancer surveillance system in the country. Strengthening cancer information and surveillance systems to monitor the progress and to evaluate the outcomes of cancer control actions is one of the seven policy objectives of the national policy and strategic framework on prevention and control of cancers in Sri Lanka which was launched in 2015. It is also one of the prioritised activities of the '*National Multi-sectoral Action Plan for the Prevention & Control of NonCommunicable Diseases of years 2016 – 2020'.*

I would like to appreciate the untiring efforts of Director and the staff of the National Cancer Control Programme and other stakeholders in expediting the process of cancer registration system in Sri Lanka to comply with the demand for latest information. I also hope policy planners, health administrators, health programme managers, clinicians and the researchers will utilize this information maximally for performing their duties at respective fields of work.

Dr. Champika Wickramasingha
Deputy Director General of Non Communicable Diseases

Forward



The process of continuing, systematic collection, storage, analysis, interpretation & dissemination of information on reportable malignancies is called the cancer surveillance / cancer registration system in the country. The human and physical resource organization for conducting the cancer surveillance is called the cancer registry. Publication of cancer incidence data is one of the key tasks of Sri Lanka Cancer Registry (SLCR) and this is the 12th edition of SLCR.

Over the years National Cancer Control Programme has taken several initiatives with the guidance of National Advisory Committee on Prevention & Control of Cancers to integrate cancer surveillance at cancer treatment centres and expedite the process of cancer surveillance with special emphasis to improve the timeliness & coverage of cancer incidence data.

The active participation of stakeholders including the Ministry of Health officials, staff of cancer treatment centres, histopathology, haematology and oral pathology laboratories, OMF units, professional colleges, academia, WHO country office and the International Agency for Research on Cancer (IARC) of WHO were immensely helpful in further strengthening of SLCR. The team work of deputy director and the staff of NCCP are sincerely appreciated as without their dedication and determination generating this kind of publication is impossible.

I hope this publication will be utilized maximally for programme planning, resource allocation, programme implementation, monitoring, evaluation and conducting cancer research. NCCP also appreciates the suggestions for improving future publications.

Dr Sudath Samaraweera
Director
National Cancer Control Programme

Table of Contents

	Page No.
Contributors	iii
Message from Director General of Health Services	v
Message from Deputy Director General of Non Communicable Diseases	vii
Forward	ix
Table of Contents	xi
List of Tables	xi
List of Figures	xii
Executive summary	1
Introduction	1
Methodology	2
Staging information of common cancers- 2010	61
List of References	81
Appendix Statistical Terminology	82

List of Tables

Table No.		Page No.
01	General population: Sex distribution	3
02	Denominators used for calculations in the cancer registry	3
03	Statistics on doctors, hospitals and hospital beds	3
04	Cancer incidence by sex, 1985-2010	4
05	Deaths due to neoplasms by sex, 2001-2010	5
06	Mortality rates by site, 2010	6
07	Cancer Incidence in Sri Lanka- 2010	7
08	Overall cancer incidence, 2010 by age and sex	7
09	Leading cancer sites-2010	8
10	Cumulative Incidence Rate (%) and Lifetime Risk (0-74 years) of leading cancer sites- 2010	9
11	Cancer cases by age group-Male 2010	16
12	Cancer cases by age group-Female 2010	18
13	Cancer cases by ethnicity, sex and sub-site, 2010	20
14	Cancer incidence by site and histological type, 2010	22
15	Lip, oral cavity and pharynx- Incidence data 2010	41
16	Lip and anterior part of oral cavity -Incidence data 2010	43
17	Posterior part of oral cavity and pharynx -Incidence data 2010	44
18	Oesophagus- Incidence data 2010	45
19	Stomach- Incidence data 2010	46
20	Colon - Incidence data 2010	47
21	Colon and rectum- Incidence data 2010	48
22	Rectum, anal canal and anus- Incidence data 2010	49
23	Larynx- Incidence data 2010	50
24	Trachea, bronchus and lungs- Incidence data 2010	51
25	Hematopoietic and reticuloendothelial system - Incidence data 2010	52
26	Skin - Incidence data 2010	53
27	Breast- Incidence data 2010	54
28	Cervix uteri- Incidence data 2010	55

Table No.		Page No.
29	Ovary - Incidence data 2010	56
30	Prostate gland - Incidence data 2010	57
31	Urinary bladder - Incidence data 2010	58
32	Brain - Incidence data 2010	59
33	Thyroid gland - Incidence data 2010	60
34	Basis of diagnosis of cancer patients 2010	62
35	Cancer treatment 2010	63
36	Cancer incidence by geographical area- 2010	65

List of Figures

Figure No.	Description	Page No.
01	General population in Sri Lanka by 5-year age groups	3
02	Crude Incidence Rates- Sri Lanka, 1985-2010	4
03	Age Standardised Incidence Rates- Sri Lanka, 1985-2010	5
04	Age Standardised Death Rates, 2001-2010	5
05	Cancer Incidence Rates- 2010	7
06	Age Specific Cancer Incidence Rates- 2010	8
07	Proportion of leading cancers, male- 2010	10
08	Proportion of leading cancers, female- 2010	10
09	Leading cancers by age group: 0-14 years	11
10	Leading cancers by age group: 15-34 years	12
11	Leading cancers by age group: 35-49 years	13
12	Leading cancers by age group: 50-64 years	14
13	Leading cancers by age group: 65 years & above	15
14	Age specific rates- Lip, oral cavity and pharynx	42
15	ASR, 1985-2010, Lip, oral cavity and pharynx	42
16	Age specific rates- Oesophagus	45
17	ASR, 1985-2010, Oesophagus	45
18	Age specific rates- Stomach	46
19	ASR, 1985-2010, Stomach	46
20	Age specific rates- Colon	47
21	ASR 1985-2010, Colon	47
22	Age specific rates- Colon and rectum	48
23	ASR, 1985-2010- Colon and rectum	48
24	Age specific rates- Rectum, anal canal and anus	49
25	ASR, 1985-2010, Rectum, anal canal and anus	49
26	Age specific rates- Larynx	50
27	ASR, 1985-2010, Larynx	50
28	Age specific rates- Trachea, bronchus and lungs	51
29	ASR, 1985-2010, Trachea, bronchus and lungs	51
30	Age specific rates- Hematopoietic and reticuloendothelial system	52
31	ASR, 1985-2010, Hematopoietic and reticuloendothelial system	52
32	Age specific rates- Skin	53
33	ASR, 1985-2010, Skin	53
34	Age specific rates- Breast	54
35	ASR, 1985-2010, Breast	54

Figure No.	Description	Page No.
36	Age specific rates- Cervix uteri	55
37	ASR, 1985-2010, Cervix uteri	55
38	Age specific rates- Ovary	56
39	ASR, 1985-2010, Ovary	56
40	Age specific rates- Prostate gland	57
41	ASR, 1985-2010, Prostate gland	57
42	Age specific rates- Urinary bladder	58
43	ASR, 1985-2010, Urinary bladder	58
44	Age specific rates- Brain	59
45	ASR, 1985-2010, Brain	59
46	Age specific rates- Thyroid gland	60
47	ASR, 1985-2010, Thyroid gland	60
48	Stage at diagnosis- Breast cancer	61
49	Stage at diagnosis- Cervical cancer	61
50	Stage at diagnosis- Oral cancer	61
51	Basis of diagnosis	62
52	Basis of diagnosis by major categories	62
53	Percentage of patients who received different types of treatment	64
54	Cancer incidence by districts- 2010	66
55	Male cancer incidence by districts- 2010	71
56	Female cancer incidence by districts- 2010	76

Executive summary

The 2010 publication of cancer incidence data of Sri Lanka is the 12th volume in the series of publications. This publication presents the cancer incidence data collected from 39 sources namely all nine cancer treatment centres in the country, 17 maxillo-facial surgery units, and 13 pathology laboratories. The increase in the number of cases from 2009 to 2010 was 75.

The crude incidence rate (CR) for all cancers was 82.1 per 100,000 population and the age standardised rate (ASR) was 87.3 per 100, 000 population. The most common cancer among females was breast cancer with a CR of 23.1 and an ASR of 23.0. The male cancer with the highest incidence was cancer of the 'lip, oral cavity and pharynx' (CR=18.4 and ASR =20.7). The CR of both these cancers has increased by approximately 1 per 100,000 from the levels observed in 2009.

When the top ten cancers among males, females and both sexes were considered the first four positions had remained unchanged from the previous year. From the 5th to the 8th position there was a slight interchange in the positions. The notable feature was the site 'Unknown Primary Site' which had been the 10th most cancer in 2009 in females, has been replaced by lymphoma.

The cancer with the highest life time risk of developing among females was breast cancer which was one in 40 females. The highest life time risk observed for males was also one in 40 males for lip, oral cavity and pharyngeal cancers.

The percentage of microscopically confirmed cases was 95.9% out of which 84.5% had been diagnosed by histology of the primary site.

According to the published data of the Registrar General's Department, 6438 male deaths and 5398 female deaths have occurred due to neoplasms. Out of those 6371 male and 5349 female deaths were due to cancer. A gradual increase in the proportionate mortality ratio for neoplasms could be observed from 2001 to 2010 (7.1 in 2001 to 9.1 in 2010).

Different trends in incidence (ASR) could be observed from 1985 up to 2010 for different cancer sites.
Among males, the ASR of 'lip, oral cavity and pharyngeal cancers' which had remained more or less static at 17-18 per 100,000 male population from 1985- 2000 and decreased in 2005 to 14.1, had again increased to 20.7 in 2010.

A gradual increase in the ASR was observed in cancers of the oesophagus, stomach, colon, hematopoietic system and 'trachea, bronchus and lung' in males. The ASR of cancers of prostate gland has increased (from 0.8 in 1985 to 4.4 in 2010) and cancers of the 'rectum, anal canal and anus' (from 0.7 in 1985 to 3.8 in 2010) by approximately 5 folds and bladder cancers from 0.9 in 1985 to 3.0 per 100,000 males in 2010.The observed increases could be partly due to increased detection and reporting to the registry as well as genuine increases in the incidence.

Similarly a gradual increase in incidence in female cancers could be seen in colon, 'rectum, anal canal and anus', stomach, 'trachea, bronchus and lung', hematopoietic system and skin. The ASR had remained more or less static in oral, laryngeal and bladder cancers in females. A substantial increase in the ASR was observed in breast cancers (from 9.4 in 1985 to 23.0 per 100,000 females in 2010) and cancers of the thyroid gland (from 1.7 in 1985 to 7.4 per 100,000 females in 2010). A marginal decreasing trend in the ASR was observed for uterine cervix cancers (from 10.4 in 1985 to 8.5 per 100,000 females in 2010).

Introduction

The National Cancer Control Programme which was established in 1980 made its first publication of cancer incidence data for the year 1985 in 1990. Thereafter publications were done annually for the years 1986 and 1987. Annual publication of data had stopped in 1987 due to logistic reasons and five-yearly publications had been done for the years 1990, 1995, 2000 and 2005. The annual publication of cancer incidence data was recommenced from 2006. Data collected only from the cancer treatment centres had been published till 2005. In the publications from 2006, data from oral and maxillo facial units and pathology labs have been incorporated.

Methodology

Cancer incidence data of 2010 represents data collected from all 9 (nine) cancer treatment centres in the country, 17 (seventeen) Oral & Maxillofacial Surgery Units and 13 (thirteen) Pathology laboratories of government hospitals. The data sources are given below.

Cancer Treatment Centres:
National Cancer Institute, Maharagama
Teaching Hospitals, Kandy, Karapitiya, Jaffna, Anuradapura and Batticaloa
Provincial General Hospitals Badulla, Kurunegala and Ratnapura

Oral & Maxillo- Facial Surgery Units in:
Dental Institute, Colombo
Teaching Hospitals, Anuradhapura, Colombo South, Kandy, Karapitiya and Ragama
Provincial General Hospital, Badulla
District General Hospitals, Chillaw, Gampaha, Kalutara, Matale, Matara, Polonnaruwa and Kegalle
Base Hospitals, Avissawella, Kuliyapitiya and Panadura

Pathology Laboratories in:
National Hospital Sri Lanka
De Soysa Hospital for Women
Castle Street Hospital for Women
Lady Ridgeway Hospital
Faculty of Medicine, Karapitiya
National Eye Hospital
Faculty of Dental Sciences, Peradeniya
Teaching Hospitals, Colombo North, Kurunegala, and Welisara (Chest)
District General Hospitals, Kalutara and Gampaha
Base Hospital, Wathupitiwela

Most of the cancer incidence data were collected by pre-intern medical graduates who were specially trained in data extraction from the patients' clinic files and recording. This procedure was followed in all cancer treatment centres except in Jaffna where data were collected by the medical officers in the unit and directly sent to the registry and Batticaloa and Kurunegala cancer treatment centres where collection was done by registry staff of the National Cancer Control programme. Patients' clinic record files were used to extract relevant data for the cancer registry. In places where pre-intern medical graduates were used, data retrieval was done under close supervision by registry staff initially and later, a random sample was checked to improve reliability of data.

In addition to this active data collection, data from the Oral & Maxillofacial Surgery Units and the Pathology laboratories were collected passively using data collection formats supplied by the NCCP to these institutions.

Data quality checks were made during coding of data, while data entering to CanReg 5 software and at the basic analysis level. The clinic record numbers of all data sheets suspected with errors were noted and the relevant patient files were re-examined and necessary corrections were done to the data sheets.

The date of first histological or cytological confirmation or the date of confirmation by clinical investigation was taken as the date of incidence. In instances this information was not available; date of admission to the hospital due to the malignancy was taken as the incidence date.

International Classification of Disease for Oncology (ICDO-3) was used for topographical and morphological coding. This cleaned data was then fed to the computer using CanReg5 package by two data entry operators who had been trained by the registry staff. Due to the increased number of data capturing points in 2010, especially the pathology laboratories, duplicate searching was a laborious process. All multiple entries due to patients being registered in more than one treatment centre were identified and removed from the database using the duplicate searching mechanisms in the software by matching basic information of the patient, demographic variables, topography and morphology. In addition to the duplicate search facility of CanReg5, excel sheets were also utilised to identify duplicate entries which were not identified by the Canreg5 software due to minor changes in spelling of names, addresses etc.
Cases under behaviour code '3' (Malignant primary site) only were included in the analysis.

Mortality data were calculated for all neoplasms as the previous registries also had considered both malignant and non-malignant neoplasms together. This had been done to facilitate analysing the trend in mortality due to neoplasms.

In the analysis of trends in cancer incidence, 'Age Standardised Rates' were recalculated from the age specific incidence rates from 1985 to 2000 using the standard world population used for calculation of ASR from 2005 onwards.



Figure 01: General population in Sri Lanka by 5-year age groups

Table 01: General population: Sex distribution

Population ('000)	Year									
	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010
Male	9,359	9,350	9,475	9,678	9,782	9,889	9,956	10,060	10,148	10,249
Female	9,438	9,571	9,698	9,757	9,862	9,969	10,083	10,186	10,302	10,404
Sex Ratio[1]	99.2	97.7	97.7	99.2	99.2	99.2	98.7	98.8	98.5	98.5

[1] *Number of males per 100 females*

Source: Department of Census and Statistics

Table 02: Denominators used for calculations in the cancer registry

Population ('000)	Year 2010
Male	10,249
Female	10,404
Total	20,653

Source: Department of Census and Statistics

Table 03: Statistics on doctors, hospitals and hospital beds

(Government Institutions)

	Year								
	2001	2002	2003	2005	2006	2007	2008	2009	2010
Doctors (MOO+DSS)	9,135	10,157	NA	11,152	11,460	12,337	13,337	14,783	15,807
Population per MO	2,058	1,863	NA	1,764	1,733	1,625	1518	1491	1410
Hospitals	569	576	607	608	614	615	647	642	636
Beds	57,946	59,144	59,262	61,594	67,024	68,694	67,942	70,842	72,506
Beds per 1000 population	3.1	3.1	3.1	3.2	3.4	3.4	3.4	3.5	3.5

NA- Not Available
Source: Medical Statistics Unit, Ministry of Health

Table 04: Cancer incidence by sex, 1985-2010

Year	Sex	Number	%	CR	ASR*
1985	Male	2,564	51.2	31.8	44.1
	Female	2,448	48.8	31.5	44.4
	Total	5,012		31.6	44.3
1990	Male	2,979	49.1	34.4	47.8
	Female	3,084	50.9	37.0	52.3
	Total	6,063		35.7	50.1
1995	Male	3,450	47.1	37.3	52.6
	Female	3,875	52.9	43.6	63.3
	Total	7,325		40.4	57.9
2000	Male	5,130	47.0	52.0	73.5
	Female	5,795	53.0	61.1	87.4
	Total	10,925		56.4	80.3
2005	Male	6,058	45.3	62.3	68.1
	Female	7,314	54.7	73.4	73.4
	Total	13,372		67.9	70.6
2010	Male	7,993	47.1	78.0	87.4
	Female	8,970	52.9	86.2	87.7
	Total	16,963		82.1	87.3

**All ASR values from 1985-2010 were calculated using the World Standard Population used by the International Agency of Cancer Registries.*



Figure 02: Crude Incidence Rates- Sri Lanka, 1985-2010



Figure 03: Age Standardised Incidence Rates- Sri Lanka, 1985-2010

Table 05: Deaths due to neoplasms by sex, 2001-2010

Year	Number of deaths due to neoplasms			Crude Annual Death Rate per 100,000 population			Age Standardised Death Rate per 100,000 population		Proportionate mortality ratio
	Male	Female	All	Male	Female	All	Male	Female	All
2001	4375	3688	8,063	46.7	39.1	42.9	52.1	39.9	7.1
2002	4350	3636	7,986	46.5	37.9	42.2	51.2	38.6	7.1
2003	4614	3782	8,396	48.7	38.9	43.8	53.6	39.6	7.3
2004	4942	4185	9,127	51.1	42.9	47.0	57.3	44.0	7.9
2005	4983	4420	9,403	50.9	44.8	47.9	57.0	45.8	7.1
2006	5644	4742	10,386	57.1	47.6	52.3	63.6	48.7	8.8
2007	5827	4804	10,631	58.5	47.6	53.1	65.4	48.8	8.9
2008									
2009	6105	5181	11,286	60.2	50.3	55.2	67.6	52.0	8.8
2010	6438	5398	11,836	62.8	51.9	62.8	70.9	53.5	9.1

Source: Registrar General's Department



Figure 04: Age Standardised Death Rates, 2001-2010

Table 06: Mortality rates by site, 2010

Cause of death		ICD 10 code	MALE			FEMALE		
			N0.	CDR	ASR	No.	CDR	ASR
1-027	Malignant neoplasm of lip,oral cavity and pharynx	C00-C14	833	8.1	9.1	288	2.8	2.8
1-028	Malignant neoplasm of oesophagus	C15	534	5.2	6.0	462	4.4	4.6
1-029	Malignant neoplasm of stomach	C16	333	3.2	3.7	310	3.0	3.0
1-030	Malignant neoplasm of colon, rectum and anus	C18-21	148	1.4	1.6	120	1.2	1.2
1-031	Malignant neoplasm of liver and intrahepatic bile ducts	C22	373	3.6	4.2	224	2.2	2.3
1-032	Malignant neoplasm of pancreas	C25	70	0.7	0.8	44	0.4	0.4
1-033	Malignant neoplasm of larynx	C32	79	0.8	0.9	15	0.1	0.2
1-034	Malignant neoplasm of trachea, bronchus and lung	C33-C34	764	7.5	8.5	228	2.2	2.2
1-035	Malignant melanoma of skin	C43	3	0.03	0.03	2	0.02	0.02
1-036	Malignant neoplasm of breast	C50	2	0.02	0.02	659	6.3	6.4
1-037	Malignant neoplasm of cervix uteri	C53				122	1.2	1.2
1-038	Malignant neoplasm of other and unspecified parts of uterus	C54-C55				269	2.6	2.7
1-039	Malignant neoplasm of ovary	C56				225	2.2	2.2
1-040	Malignant neoplasm of prostate	C61	132	1.3	1.5			
1-041	Malignant neoplasm of bladder	C67	104	1.0	1.1	24	0.2	0.2
1-042	Malignant neoplasm of meninges, brain and other parts of central nervous system	C70-C72	235	2.3	2.5	186	1.8	1.9
1-043	Non Hodgkin's lymphoma	C82-C85	159	1.6	1.7	88	0.8	0.8
1-044	Multiple myeloma and malignant plasma cell neoplasms	C90	62	0.6	0.7	53	0.5	0.6
1-045	Leukaemia	C91-C95	287	2.8	2.9	259	2.5	2.6
1-046	Remainder of malignant neoplasms	C17, C23-24, C26-C31, C37-C41, C44-C49, C51-C52, C57-C60, C62-C66, C68-C69, C73-C81, C88, C96-C97	2252	22.0	24.8	1862	17.9	18.5
1-047	Remainder of neoplasms	D00-D48	67	0.7	0.7	49	0.5	0.5
1-026	**Neoplasms**	**C00-D48**	**6438**	**62.8**	**70.9**	**5398**	**51.9**	**57.3**

Source: Registrar General's Department

Table 07: Cancer Incidence in Sri Lanka- 2010

Sex	Number	%	CR	ASR
Male	7993	47.1	78.0	87.4
Female	8970	52.9	86.2	87.7
Total	16963	100.0	82.1	87.3



Figure 05: Cancer Incidence Rates- 2010

Table 08: Overall cancer incidence, 2010 by age and sex

Age group	Male			Female			Total		
	Cases	Population	Incidence	Cases	Population	Incidence	Cases	Population	Incidence
Not Known	38			22			60		
0-4	142	892	15.9	94	863	10.9	236	1755	13.4
5-9	68	922	7.4	71	895	7.9	139	1817	7.6
10-14	51	943	5.4	32	916	3.5	83	1859	4.5
15-19	86	1015	8.5	79	988	8.0	165	2003	8.2
20-24	85	974	8.7	128	968	13.2	213	1942	11.0
25-29	116	799	14.5	205	832	24.6	321	1631	19.7
30-34	150	779	19.3	298	801	37.2	448	1580	28.4
35-39	174	758	23.0	516	780	66.2	690	1538	44.9
40-44	343	707	48.5	642	718	89.4	985	1425	69.1
45-49	541	615	88.0	953	635	150.1	1494	1250	119.5
50-54	913	554	164.8	1150	572	201.0	2063	1126	183.2
55-59	1033	390	264.9	1203	427	281.7	2236	817	273.7
60-64	1304	297	439.1	1213	312	388.8	2517	609	413.3
65-69	1048	225	465.8	909	260	349.6	1957	485	403.5
70-74	927	174	532.8	689	198	348.0	1616	372	434.4
75+	974	205	475.1	766	239	320.5	1740	444	391.9
Total	**7,993**	**10,249**	**78.0**	**8,970**	**10,404**	**86.2**	**16,963**	**20,653**	**82.1**



Figure 06: Age Specific Cancer Incidence Rates- 2010

Table 09: Leading cancer sites-2010

Rank	Male				Female				Total			
	Site	No.	CR	ASR	Site	No.	CR	ASR	Site	No.	CR	ASR
1	Lip, oral cavity & pharynx	1888	18.4	20.7	Breast	2401	23.1	23.0	Breast	2440	11.8	12.1
2	Trachea, bronchus and lung	806	7.9	9.0	Cervix uteri	847	8.1	8.4	Lip, oral cavity & pharynx	2422	11.7	12.7
3	Oesophagus	574	5.6	6.5	Thyroid gland	832	8.0	7.4	Cervix uteri	847	8.1	8.4
4	Colon and rectum	567	5.5	6.2	Ovary	680	6.5	6.7	Ovary	680	6.5	6.7
5	Prostate gland	480	4.7	5.5	Lip, oral cavity & pharynx	534	5.1	5.4	Colon and rectum	1083	5.2	5.6
6	Unknown primary site	436	4.3	4.8	Colon and rectum	516	5.0	5.1	Oesophagus	1070	5.2	5.7
7	Lymphoma	419	4.1	4.3	Oesophagus	496	4.8	5.1	Thyroid gland	1036	5.0	4.8
8	Larynx	384	3.7	4.3	Uterus	386	3.7	3.9	Trachea, bronchus and lung	1015	4.9	5.4
9	Leukaemia	354	3.5	3.7	Leukaemia	290	2.8	3.0	Prostate gland	480	4.7	5.5
10	Bladder	269	2.6	3.0	Lymphoma	275	2.6	2.6	Unknown primary site	708	3.4	3.7
	All sites	**7993**	**78.0**	**87.4**	**All sites**	**8970**	**86.2**	**87.7**	**All sites**	**16963**	**82.1**	**87.3**

CR: Crude rate per 100,000 population

ASR: Age standardized rate per 100,000 world population

The cumulative incidence rate given in Table 10 is a summary measure of the age specific incidence rates from 0-74 years. It is the summation of values of all the age specific incidence rates multiplied by 5 (as incidence rates were calculated for 5 year age groups) expressed per 100 persons in the population.

The life time risk of developing the leading cancers is also given in Table 10. The life time risk is given as a percentage, the risk of developing a particular cancer per 100 persons in the population as well as risk of developing a particular cancer given as number of persons per new case developed. One in every 10 males and one in every 11 females have a risk of developing cancer during their lifetime (0-74 years).

Table 10: Cumulative Incidence Rate (%) and Lifetime Risk (0-74 years) of leading cancer sites- 2010

ICD O Code	Site	Male		Female		Total	
		Cumulative Rate	Lifetime Risk	Cumulative Rate	Lifetime Risk	Cumulative Rate	Lifetime Risk
			%[1]		%		%
			(n)[2]		(n)		(n)
C00-C06, C09-C14	Lip, oral cavity and pharynx	2.559	2.56 (40)	0.655	0.652 (153)	1.563	1.551 (64)
C15	Oesophagus	0.825	0.822 (122)	0.622	0.620 (161)	0.719	0.717 (140)
C16	Stomach	0.310	0.310 (323)	0.116	0.116 (863)	0.208	0.208 (480)
C18-C20	Colon and rectum	0.805	0.802 (125)	0.635	0.633 (158)	0.716	0.713 (140)
C32	Larynx	0.544	0.543 (184)	0.053	0.053 (1889)	0.287	0.286 (349)
C33-C34	Trachea, bronchus and lung	1.190	1.183 (85)	0.254	0.254 (394)	0.699	0.697 (143)
C50	Breast	0.048	0.048 (2069)	2.558	2.525 (40)	1.347	1.338 (75)
C53	Cervix uteri	-	-	1.023	1.017 (98)	-	-
C54-C55	Uterus	-	-	0.508	0.507 (197)	-	-
C56	Ovary	-	-	0.764	0.761 (131)	-	-
C61	Prostate gland	0.732	0.729 (137)	-	-	-	-
C73	Thyroid gland	0.215	0.215 (465)	0.686	0.684 (146)	0.456	0.455 (220)
C80	Unknown primary site	0.629	0.627 (160)	0.303	0.302 (331)	0.458	0.457 (219)
	Lymphoma	0.462	0.461 (217)	0.272	0.272 (368)	0.363	0.363 (276)
	Leukaemia	0.312	0.312 (321)	0.278	0.278 (360)	0.296	0.295 (339)
	All sites	10.532	9.996 (10)	9.901	9.427 (11)	10.172	9.672 (10)

1- %- Life time risk as a percentage (per 100 persons)

2- (n)- Number of population per one new case detected



Figure 07: Proportion of leading cancers, male- 2010



Figure 08: Proportion of leading cancers, female- 2010





Figure 09: Leading cancers by age group: 0-14 years





Figure 10: Leading cancers by age group: 15-34 years





Figure 11: Leading cancers by age group: 35-49 years





Figure 12: Leading cancers by age group: 50-64 years





Figure 13: Leading cancers by age group: 65 years & above

Table 11: Cancer cases by age group-Male 2010

ICD O Code and Site	Age Group																	
	Not Kn	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	To-tal
C00 Lip	0	0	0	0	0	0	0	0	1	5	2	11	9	11	8	5	12	64
C01 Base of tongue	0	0	0	0	0	0	0	0	1	7	10	15	19	23	14	14	14	117
C02 Other and unspecified parts of tongue	1	0	0	0	0	1	0	3	8	19	51	60	63	72	38	30	27	373
C03 Gum	0	0	0	0	0	0	2	1	2	4	10	12	14	14	20	15	21	115
C04 Floor of mouth	0	0	0	0	0	0	0	2	2	3	7	25	13	18	15	7	9	101
C05 Palate	0	0	0	0	0	0	0	1	2	3	8	14	17	20	14	12	13	104
C06 Other and unspecified parts of mouth	2	0	0	0	1	0	1	2	1	17	39	57	79	73	79	64	100	515
C07 Parotid gland	0	0	0	0	1	1	0	4	3	2	1	4	8	3	2	2	1	32
C08 Other and unspecified major salivary glands	1	0	0	0	1	0	1	0	0	1	2	3	1	1	3	1	4	19
C09 Tonsil	0	0	1	0	0	2	2	2	1	7	10	18	16	21	17	25	9	131
C10 Oropharynx	0	0	0	0	0	0	2	0	2	5	10	10	23	15	8	5	6	86
C11 Nasopharynx	0	0	0	0	1	0	2	0	2	0	2	3	3	2	5	7	1	28
C12 Pyriform sinus	0	0	0	0	0	0	0	1	4	8	16	23	22	34	27	16	18	169
C13 Hypopharynx	0	0	0	0	0	0	0	0	1	1	5	2	2	4	5	6	0	26
C14 Other and ill-defined sites in lip, oral cavity and pharynx	0	0	0	0	0	0	0	0	0	1	4	12	10	9	6	9	8	59
C15 Oesophagus	3	0	0	0	0	0	1	3	7	20	38	65	89	124	92	65	67	574
C16 Stomach	0	0	0	0	0	0	3	1	3	6	18	27	42	48	29	22	27	226
C17 Small intestine	0	0	0	0	2	0	0	2	1	3	2	2	2	2	4	1	1	22
C18 Colon	4	0	1	0	2	5	2	7	7	21	17	29	33	33	22	24	14	221
C19 Rectosigmoid junction	0	0	0	0	0	0	1	0	2	0	0	4	2	10	5	3	3	30
C20 Rectum	2	0	0	0	0	0	2	4	6	10	18	37	39	53	52	43	50	316
C21 Anus and anal canal	0	0	0	0	0	0	0	0	1	3	1	3	7	6	2	1	4	28
C22 Liver and intrahepatic bile ducts	2	2	0	0	0	1	2	0	1	5	4	10	17	30	23	23	12	132
C23 Gallbladder	0	0	0	0	0	0	0	0	0	0	0	2	2	3	2	0	1	10
C24 Other and unspecified parts of biliary tract	0	0	0	0	0	1	1	0	0	1	3	3	5	10	3	2	3	32
C25 Pancreas	0	0	0	0	0	0	0	1	1	2	6	4	6	8	5	2	11	46
C26 Other and ill-defined digestive organs	0	0	0	0	0	0	0	1	0	2	1	1	1	1	3	2	1	13
C30 Nasal cavity and middle ear	0	0	0	1	1	0	0	2	0	1	0	4	1	5	4	1	3	23
C31 Accessory sinuses	1	0	0	0	0	1	0	1	0	0	5	4	2	7	1	3	2	27
C32 Larynx	1	0	0	0	0	0	2	1	3	12	20	52	78	64	63	42	46	384
C33 Trachea	0	0	0	0	0	0	0	0	0	0	2	0	2	0	1	0	0	5
C34 Bronchus and lung	6	1	1	0	0	0	3	8	7	29	52	107	103	165	122	115	82	801
C37 Thymus	1	0	0	0	0	0	0	0	2	0	2	1	2	3	1	0	0	12
C38 Heart, mediastinum and pleura	0	0	0	2	0	3	1	1	1	0	0	1	0	2	1	0	1	13
C40 Bones, joints and articular cartilage of limbs	0	0	3	3	12	6	7	0	1	2	1	0	5	2	1	1	0	44
C41 Bones, joints and articular cartilage of other and unspecified sites	0	2	1	0	3	1	4	2	2	3	2	2	2	1	1	0	0	26
C42 Hematopoietic and reticuloendothelial systems	2	55	28	21	22	24	18	27	20	22	24	41	41	72	51	37	50	555
C44 Skin	0	0	1	1	0	2	5	2	10	7	11	25	19	15	22	15	23	158

ICD O Code and Site	Age Group																	
	Not Kn	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	To-tal
C47 Peripheral nerves and autonomic nervous system	0	1	3	0	0	1	0	0	1	1	1	0	2	0	0	0	0	10
C48 Retroperitoneum and peritoneum	0	0	0	0	0	0	1	0	0	0	1	2	1	1	0	0	0	6
C49 Connective, subcutaneous and other soft tissues	0	13	2	1	3	7	3	6	9	6	4	7	12	6	9	1	10	99
C50 Breast	0	0	1	0	0	1	0	0	1	4	2	2	2	6	6	5	9	39
C60 Penis	0	0	0	0	1	0	0	1	2	7	3	11	9	8	9	17	8	76
C61 Prostate gland	2	0	0	0	0	0	0	1	0	0	3	9	35	64	94	125	147	480
C62 Testis	0	5	0	0	3	3	8	6	3	3	6	2	0	2	1	1	2	45
C63 Other and unspecified male genital organs	0	0	0	0	0	0	0	0	0	0	0	0	0	3	1	0	2	6
C64 Kidney	0	13	4	0	1	0	0	4	3	9	10	13	9	21	17	7	5	116
C66 Ureter	0	0	0	0	0	0	0	0	0	1	1	1	0	0	0	1	0	4
C67 Bladder	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1
C68 Other and unspecified urinary organs	2	0	0	0	0	0	1	1	3	5	9	22	29	53	37	43	64	269
C69 Eye and adnexa	0	25	1	0	0	0	0	0	0	0	0	1	0	2	2	0	1	32
C70 Meninges	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1
C71 Brain	0	3	8	9	4	4	3	3	15	8	16	19	20	7	7	3	3	132
C72 Spinal cord, cranial nerves and other parts of central nervous system	0	1	2	1	0	0	0	0	2	1	0	0	0	1	0	0	0	8
C73 Thyroid gland	2	0	0	1	6	9	16	17	19	18	27	20	17	23	13	11	5	204
C74 Adrenal gland	0	9	1	1	0	0	0	0	1	2	2	0	1	1	0	0	2	20
C75 Other endocrine glands and related structures	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	2
C76 Other and ill-defined sites	0	5	0	0	0	0	0	0	0	1	0	0	0	1	0	0	2	9
C77 Lymph nodes	1	4	9	10	22	11	18	25	6	20	24	42	37	47	30	22	33	361
C80 Unknown primary site	5	3	0	0	0	1	4	6	4	25	28	69	60	73	50	71	37	436
Total	38	142	68	51	86	85	116	150	174	343	541	913	1033	1304	1048	927	974	7993

Table 12: Cancer cases by age group-Female 2010

ICD O Code and Site	Age Group																	
	Not Kn	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	Total
C00 Lip	1	0	0	0	0	0	0	0	0	0	1	0	1	6	0	6	11	26
C01 Base of tongue	0	0	0	0	0	0	0	0	0	0	2	1	2	1	1	4	2	13
C02 Other and unspecified parts of tongue	0	0	0	0	1	0	0	2	5	5	7	7	4	13	6	10	10	70
C03 Gum	0	0	0	0	0	0	0	1	3	4	3	1	5	10	8	4	12	51
C04 Floor of mouth	0	0	0	0	0	0	0	2	1	0	1	1	1	5	2	2	1	16
C05 Palate	0	0	0	0	0	0	1	0	2	2	0	6	2	7	4	3	10	37
C06 Other and unspecified parts of mouth	0	0	0	0	0	0	0	3	3	0	14	19	23	36	38	35	41	212
C07 Parotid gland	0	0	0	1	0	2	1	1	6	0	2	3	1	3	2	3	2	27
C08 Other and unspecified major salivary glands	0	0	0	0	0	0	0	1	1	1	1	2	2	1	0	1	3	13
C09 Tonsil	0	0	0	0	0	0	0	1	1	0	0	3	4	5	5	3	1	23
C10 Oropharynx	0	0	0	0	0	0	0	0	0	0	0	0	1	2	0	2	1	6
C11 Nasopharynx	0	0	0	0	1	1	0	0	1	1	2	2	1	0	1	1	1	12
C12 Pyriform sinus	0	0	0	0	0	0	1	0	0	1	2	1	4	2	1	1	5	18
C13 Hypopharynx	0	0	0	0	0	1	0	0	1	0	2	2	6	4	3	2	1	22
C14 Other and ill-defined sites in lip, oral cavity and pharynx	0	0	0	0	0	0	0	1	1	1	3	4	5	2	3	5	3	28
C15 Oesophagus	1	0	0	0	0	1	1	0	6	12	23	55	51	95	84	67	100	496
C16 Stomach	0	0	0	0	0	1	2	0	4	2	10	13	17	19	8	10	11	97
C17 Small intestine	0	0	0	0	0	1	0	1	3	2	1	0	4	4	1	1	1	19
C18 Colon	2	0	0	0	0	2	1	4	13	12	22	28	30	32	25	20	31	222
C19 Rectosigmoid junction	0	0	0	0	0	0	0	0	0	3	6	8	5	6	7	7	4	46
C20 Rectum	0	0	0	0	1	0	2	6	2	13	10	24	44	40	26	40	40	248
C21 Anus and anal canal	0	0	0	0	0	1	0	0	2	1	1	1	1	2	4	5	4	22
C22 Liver and intrahepatic bile ducts	0	7	2	0	1	0	1	0	3	4	2	4	2	2	6	2	2	38
C23 Gallbladder	0	0	0	0	0	0	0	0	0	0	2	2	5	4	4	2	5	24
C24 Other and unspecified parts of biliary tract	1	0	0	0	0	0	0	0	1	0	0	3	2	8	4	2	3	24
C25 Pancreas	0	0	0	0	0	0	1	0	0	7	8	10	3	10	4	8	5	56
C26 Other and ill-defined digestive organs	0	0	0	0	1	0	3	2	0	0	0	1	1	0	0	1	0	9
C30 Nasal cavity and middle ear	0	0	0	0	0	0	0	0	0	1	1	1	1	1	0	2	1	8
C31 Accessory sinuses	0	0	0	0	0	0	0	2	2	0	1	1	0	3	1	1	3	14
C32 Larynx	0	0	0	0	0	1	0	0	2	1	1	3	4	7	7	7	3	36
C34 Bronchus and lung	0	0	0	0	0	2	3	3	15	12	16	20	33	35	24	24	22	209
C37 Thymus	0	0	0	0	0	0	1	2	0	1	0	0	2	1	0	2	0	9
C38 Heart, mediastinum and pleura	0	0	0	0	0	0	0	0	0	1	0	0	0	3	2	0	0	6
C40 Bones, joints and articular cartilage of limbs	0	0	1	6	7	2	2	1	0	0	3	1	1	1	1	0	0	26
C41 Bones, joints and articular cartilage of other and unspecified sites	0	1	3	3	1	5	1	0	1	1	2	5	0	3	2	0	0	28
C42 Hematopoietic and reticuloendothelial systems	0	32	24	9	22	16	18	19	21	18	32	50	51	56	40	54	37	499
C44 Skin	1	0	1	0	2	2	1	3	9	3	8	12	18	14	19	23	25	141

ICD O Code and Site	Age Group																	
	Not Kn	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	Total
C47 Peripheral nerves and autonomic nervous system	0	0	0	1	0	0	0	0	1	1	0	2	0	0	0	0	0	5
C48 Retroperitoneum and peritoneum	0	3	0	1	0	0	1	1	0	3	2	2	4	3	6	0	3	29
C49 Connective, subcutaneous and other soft tissues	0	7	4	1	1	4	3	4	1	5	5	3	3	7	2	4	5	59
C50 Breast	7	0	0	1	1	2	23	65	173	271	366	388	349	312	195	115	133	2401
C51 Vulva	0	0	0	0	0	0	0	1	1	2	1	3	1	4	4	5	13	35
C52 Vagina	0	0	0	0	0	0	0	0	0	1	2	1	4	5	6	2	2	23
C53 Cervix uteri	3	0	0	0	0	0	1	11	33	49	120	127	130	140	98	75	60	847
C54 Corpus uteri	0	0	0	0	1	0	0	4	1	10	26	49	88	64	54	24	9	330
C55 Uterus, NOS	0	0	0	0	0	0	1	0	1	5	7	8	14	5	9	2	4	56
C56 Ovary	3	3	1	1	6	8	21	24	30	54	75	109	108	97	83	29	28	680
C57 Other and unspecified female genital organs	0	0	0	0	0	0	0	1	0	0	1	0	0	2	1	2	0	7
C58 Placenta	0	0	0	0	2	2	7	3	2	2	1	1	0	0	0	0	0	20
C64 Kidney	0	7	1	0	0	2	0	2	0	1	1	10	5	11	5	5	3	53
C65 Renal pelvis	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	2	4
C67 Bladder	0	0	0	0	0	0	2	1	0	3	4	3	5	9	10	9	20	66
C69 Eye and adnexa	0	10	4	0	0	0	0	0	1	0	0	0	1	1	1	0	1	19
C70 Meninges	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1
C71 Brain	1	6	13	3	2	4	3	8	12	5	9	13	8	11	4	4	2	108
C72 Spinal cord, cranial nerves and other parts of central nervous system	0	0	1	1	2	1	0	0	1	0	0	1	1	0	0	0	0	8
C73 Thyroid gland	0	1	2	2	16	53	89	101	120	89	106	85	69	37	32	13	17	832
C74 Adrenal gland	0	9	6	0	0	0	0	1	1	2	0	2	4	0	0	1	0	26
C76 Other and ill-defined sites	0	4	0	0	0	0	0	1	0	0	3	1	1	1	3	1	0	15
C77 Lymph nodes	1	2	7	2	8	14	10	9	20	16	10	16	30	22	23	12	21	223
C80 Unknown primary site	1	2	1	0	3	0	3	6	9	14	25	32	40	39	29	26	42	272
Total	**22**	**94**	**71**	**32**	**79**	**128**	**205**	**298**	**516**	**642**	**953**	**1150**	**1203**	**1213**	**909**	**689**	**766**	**8970**

Table 13: Cancer cases by ethnicity, sex and sub-site, 2010

ICD O Code and Site	All		Sinhala		Tamil		Muslim		Other		Unknown	
	Male	Female	Male	Female	Male	Female	Male	Female	Male	Female	Male	Female
C00 Lip	64	26	55	12	4	9	5	4	0	0	0	1
C01 Base of tongue	117	13	97	11	11	1	2	0	6	1	1	0
C02 Other and unspecified parts of tongue	373	70	327	52	28	12	7	3	8	3	3	0
C03 Gum	115	51	92	35	15	10	4	5	3	1	1	0
C04 Floor of mouth	101	16	86	13	7	2	3	1	3	0	2	0
C05 Palate	104	37	85	25	16	9	0	3	3	0	0	0
C06 Other and unspecified parts of mouth	515	212	417	123	63	49	15	32	13	3	7	5
C07 Parotid gland	32	27	29	25	2	2	1	0	0	0	0	0
C08 Other and unspecified major salivary glands	19	13	17	9	0	4	2	0	0	0	0	0
C09 Tonsil	131	23	115	17	8	3	4	0	4	1	0	2
C10 Oropharynx	86	6	67	4	13	0	6	1	0	0	0	1
C11 Nasopharynx	28	12	25	10	1	1	1	1	1	0	0	0
C12 Pyriform sinus	169	18	136	10	25	5	3	2	4	1	1	0
C13 Hypopharynx	26	22	21	12	3	9	1	0	0	1	1	0
C14 Other and ill-defined sites in lip, oral cavity and pharynx	59	28	46	19	10	6	2	2	1	0	0	1
C15 Oesophagus	574	496	471	362	63	106	22	18	15	6	3	4
C16 Stomach	226	97	177	59	32	22	11	11	6	3	0	2
C17 Small intestine	22	19	20	16	0	2	1	1	1	0	0	0
C18 Colon	221	222	191	188	14	13	11	14	2	6	3	1
C19 Rectosigmoid junction	30	46	28	37	2	3	0	5	0	1	0	0
C20 Rectum	316	248	273	214	19	19	13	11	10	4	1	0
C21 Anus and anal canal	28	22	23	17	2	1	2	2	1	1	0	1
C22 Liver and intrahepatic bile ducts	132	38	115	28	7	3	6	3	4	4	0	0
C23 Gallbladder	10	24	7	18	1	2	1	3	0	1	1	0
C24 Other and unspecified parts of biliary tract	32	24	24	13	4	9	3	1	1	0	0	1
C25 Pancreas	46	56	39	45	5	8	2	3	0	0	0	0
C26 Other and ill-defined digestive organs	13	9	11	7	1	0	1	2	0	0	0	0
C30 Nasal cavity and middle ear	23	8	18	6	5	0	0	2	0	0	0	0
C31 Accessory sinuses	27	14	19	10	5	3	2	1	0	0	1	0
C32 Larynx	384	36	323	27	34	8	15	1	9	0	3	0
C33 Trachea	5	0	5	0	0	0	0	0	0	0	0	0
C34 Bronchus and lung	801	209	638	160	83	25	59	16	15	7	6	1
C37 Thymus	12	9	11	7	1	1	0	0	0	1	0	0
C38 Heart, mediastinum and pleura	13	6	10	4	2	1	0	1	1	0	0	0
C40 Bones, joints and articular cartilage of limbs	44	26	38	18	3	3	3	4	0	1	0	0
C41 Bones, joints and articular cartilage of other and unspecified sites	26	28	18	24	3	2	4	2	1	0	0	0
C42 Hematopoietic and reticuloendothelial systems	555	499	452	398	52	47	36	41	13	11	2	2
C44 Skin	158	141	128	108	14	19	14	10	2	3	0	1
C47 Peripheral nerves and autonomic nervous system	10	5	7	5	1	0	1	0	0	0	1	0
C48 Retroperitoneum and peritoneum	6	29	5	21	1	4	0	1	0	3	0	0
C49 Connective, subcutaneous and other soft tissues	99	59	82	38	8	8	6	13	2	0	1	0
C50 Breast	39	2401	24	1937	14	199	1	195	0	61	0	9
C51 Vulva		35		29		2		3		1		0
C52 Vagina		23		20		3		0		0		0
C53 Cervix uteri		847		635		161		31		14		6

ICD O Code and Site	All		Sinhala		Tamil		Muslim		Other		Unknown	
	Male	Female	Male	Female	Male	Female	Male	Female	Male	Female	Male	Female
C54 Corpus uteri		330		273		28		23		6		0
C55 Uterus, NOS		56		48		4		1		2		1
C56 Ovary		680		568		63		38		10		1
C57 Other and unspecified female genital organs		7		5		2		0		0		0
C58 Placenta		20		16		1		2		1		0
C60 Penis	76		57		16		0		1		2	
C61 Prostate gland	480		378		53		33		14		2	
C62 Testis	45		41		4		0		0		0	
C63 Other and unspecified male genital organs	6		4		1		0		1		0	
C64 Kidney	116	53	92	43	13	3	7	7	3	0	1	0
C65 Renal pelvis	4	4	3	3	0	1	0	0	1	0	0	0
C66 Ureter	1		1		0		0		0		0	
C67 Bladder	269	66	218	54	22	6	20	4	8	1	1	1
C69 Eye and adnexa	32	19	29	15	1	0	1	3	0	1	1	0
C70 Meninges	1	1	1	1	0	0	0	0	0	0	0	0
C71 Brain	132	108	110	83	14	10	6	11	2	4	0	0
C72 Spinal cord, cranial nerves and other parts of central nervous system	8	8	5	6	2	0	1	1	0	1	0	0
C73 Thyroid gland	204	832	168	699	21	48	8	48	6	35	1	2
C74 Adrenal gland	20	26	15	20	2	2	3	3	0	1	0	0
C75 Other endocrine glands and related structures	2	0	2	0	0	0	0	0	0	0	0	0
C76 Other and ill-defined sites	9	15	7	12	1	1	0	2	1	0	0	0
C77 Lymph nodes	361	223	298	160	22	24	27	27	13	9	1	3
C80 Unknown primary site	436	272	352	218	43	27	31	19	7	6	3	2
Total	**7993**	**8970**	**6553**	**7052**		**797**	**407**	**638**		**186**	**50**	**48**

Table 14: Cancer incidence by site and histological type, 2010

Site and histology	Male		Female		Total	
C00 LIp	**No**	**%**	**No**	**%**	**No**	**%**
8000 Neoplasm, malignant	1	1.6%	0	0.0%	1	1.1%
8010 Carcinoma, NOS	0	0.0%	1	3.8%	1	1.1%
8032 Spindle cell carcinoma, NOS	0	0.0%	1	3.8%	1	1.1%
8051 Verrucous carcinoma, NOS	2	3.1%	3	11.5%	5	5.6%
8070 Squamous cell carcinoma, NOS	60	93.8%	21	80.8%	81	90.0%
8071 Squamous cell carcinoma, keratinizing, NOS	1	1.6%	0	0.0%	1	1.1%
Total	**64**	**100.0%**	**26**	**100.0%**	**90**	**100.0%**
C01 Base of tongue	**No**	**%**	**No**	**%**	**No**	**%**
8000 Neoplasm, malignant	4	3.4%	1	7.7%	5	3.8%
8010 Carcinoma, NOS	3	2.6%	0	0.0%	3	2.3%
8070 Squamous cell carcinoma, NOS	105	89.7%	11	84.6%	116	89.2%
8071 Squamous cell carcinoma, keratinizing, NOS	1	0.9%	0	0.0%	1	0.8%
8083 Basaloid squamous cell carcinoma	1	0.9%	0	0.0%	1	0.8%
8200 Adenoid cystic carcinoma	0	0.0%	1	7.7%	1	0.8%
8430 Mucoepidermoid carcinoma	2	1.7%	0	0.0%	2	1.5%
9680 Malignant lymphoma, large B-cell, diffuse, NOS	1	0.9%	0	0.0%	1	0.8%
Total	**117**	**100.0%**	**13**	**100.0%**	**130**	**100.0%**
C02 Other and unspecified parts of tongue	**No**	**%**	**No**	**%**	**No**	**%**
8000 Neoplasm, malignant	4	1.1%	1	1.4%	5	1.1%
8010 Carcinoma, NOS	0	0.0%	1	1.4%	1	0.2%
8070 Squamous cell carcinoma, NOS	364	97.6%	64	91.4%	428	96.6%
8071 Squamous cell carcinoma, keratinizing, NOS	1	0.3%	0	0.0%	1	0.2%
8072 Squamous cell carcinoma, large cell, nonkeratinizing,	1	0.3%	1	1.4%	2	0.5%
8083 Basaloid squamous cell carcinoma	2	0.5%	0	0.0%	2	0.5%
8200 Adenoid cystic carcinoma	0	0.0%	1	1.4%	1	0.2%
8430 Mucoepidermoid carcinoma	0	0.0%	1	1.4%	1	0.2%
8912 Spindle cell rhabdomyosarcoma	1	0.3%	0	0.0%	1	0.2%
9591 Malignant lymphoma, non-Hodgkin, NOS	0	0.0%	1	1.4%	1	0.2%
Total	**373**	**100.0%**	**70**	**100.0%**	**443**	**100.0%**
C03 Gum	**No**	**%**	**No**	**%**	**No**	**%**
8000 Neoplasm, malignant	4	3.5%	3	5.9%	7	4.2%
8010 Carcinoma, NOS	2	1.7%	1	2.0%	3	1.8%
8070 Squamous cell carcinoma, NOS	101	87.8%	41	80.4%	142	85.5%
8200 Adenoid cystic carcinoma	2	1.7%	3	5.9%	5	3.0%
8430 Mucoepidermoid carcinoma	5	4.3%	2	3.9%	7	4.2%
8982 Malignant myoepithelioma	0	0.0%	1	2.0%	1	0.6%
9680 Malignant lymphoma, large B-cell, diffuse, NOS	1	0.9%	0	0.0%	1	0.6%
Total	**115**	**100.0%**	**51**	**100.0%**	**166**	**100.0%**
C04 Floor of mouth	**No**	**%**	**No**	**%**	**No**	**%**
8000 Neoplasm, malignant	4	4.0%	0	0.0%	4	3.4%
8051 Verrucous carcinoma, NOS	0	0.0%	1	6.3%	1	0.9%
8070 Squamous cell carcinoma, NOS	92	91.1%	10	62.5%	102	87.2%
8083 Basaloid squamous cell carcinoma	2	2.0%	0	0.0%	2	1.7%
8200 Adenoid cystic carcinoma	3	3.0%	2	12.5%	5	4.3%
8310 Clear cell adenocarcinoma, NOS	0	0.0%	1	6.3%	1	0.9%
8430 Mucoepidermoid carcinoma	0	0.0%	2	12.5%	2	1.7%
Total	**101**	**100.0%**	**16**	**100.0%**	**117**	**100.0%**
C05 Palate	**No**	**%**	**No**	**%**	**No**	**%**
8000 Neoplasm, malignant	3	2.9%	3	8.1%	6	4.3%
8010 Carcinoma, NOS	4	3.8%	1	2.7%	5	3.5%

Site and histology	Male		Female		Total	
8051 Verrucous carcinoma, NOS	2	1.9%	0	0.0%	2	1.4%
8070 Squamous cell carcinoma, NOS	89	85.6%	24	64.9%	113	80.1%
8071 Squamous cell carcinoma, keratinizing, NOS	1	1.0%	0	0.0%	1	0.7%
8140 Adenocarcinoma, NOS	0	0.0%	1	2.7%	1	0.7%
8200 Adenoid cystic carcinoma	3	2.9%	3	8.1%	6	4.3%
8430 Mucoepidermoid carcinoma	1	1.0%	5	13.5%	6	4.3%
8720 Malignant melanoma, NOS	1	1.0%	0	0.0%	1	0.7%
Total	**104**	**100.0%**	**37**	**100.0%**	**141**	**100.0%**
C06 Other and unspecified parts of mouth	**No**	**%**	**No**	**%**	**No**	**%**
8000 Neoplasm, malignant	19	3.7%	11	5.2%	30	4.1%
8010 Carcinoma, NOS	10	1.9%	5	2.4%	15	2.1%
8051 Verrucous carcinoma, NOS	14	2.7%	6	2.8%	20	2.8%
8070 Squamous cell carcinoma, NOS	459	89.1%	180	84.9%	639	87.9%
8071 Squamous cell carcinoma, keratinizing, NOS	2	0.4%	0	0.0%	2	0.3%
8075 Squamous cell carcinoma, adenoid	1	0.2%	1	0.5%	2	0.3%
8140 Adenocarcinoma, NOS	2	0.4%	2	0.9%	4	0.6%
8200 Adenoid cystic carcinoma	4	0.8%	4	1.9%	8	1.1%
8430 Mucoepidermoid carcinoma	1	0.2%	1	0.5%	2	0.3%
8550 Acinar cell carcinoma	2	0.4%	0	0.0%	2	0.3%
8720 Malignant melanoma, NOS	0	0.0%	2	0.9%	2	0.3%
8980 Carcinosarcoma, NOS	1	0.2%	0	0.0%	1	0.1%
Total	**515**	**100.0%**	**212**	**100.0%**	**727**	**100.0%**
C07 Parotid gland	**No**	**%**	**No**	**%**	**No**	**%**
8000 Neoplasm, malignant	1	3.1%	0	0.0%	1	1.7%
8022 Pleomorphic carcinoma	1	3.1%	0	0.0%	1	1.7%
8070 Squamous cell carcinoma, NOS	3	9.4%	1	3.7%	4	6.8%
8140 Adenocarcinoma, NOS	2	6.3%	6	22.2%	8	13.6%
8200 Adenoid cystic carcinoma	2	6.3%	4	14.8%	6	10.2%
8430 Mucoepidermoid carcinoma	11	34.4%	9	33.3%	20	33.9%
C07 Parotid gland	**No**	**%**	**No**	**%**	**No**	**%**
8500 Infiltrating duct carcinoma, NOS	5	15.6%	0	0.0%	5	8.5%
8550 Acinar cell carcinoma	3	9.4%	4	14.8%	7	11.9%
8562 Epithelial-myoepithelial carcinoma	1	3.1%	0	0.0%	1	1.7%
8940 Mixed tumor, malignant, NOS	0	0.0%	1	3.7%	1	1.7%
8941 Carcinoma in pleomorphic adenoma	0	0.0%	1	3.7%	1	1.7%
8982 Malignant myoepithelioma	1	3.1%	1	3.7%	2	3.4%
9591 Malignant lymphoma, non-Hodgkin, NOS	1	3.1%	0	0.0%	1	1.7%
9734 Plasmacytoma, extramedullary	1	3.1%	0	0.0%	1	1.7%
Total	**32**	**100.0%**	**27**	**100.0%**	**59**	**100.0%**
C08 Other and unspecified major salivary glands	**No**	**%**	**No**	**%**	**No**	**%**
8000 Neoplasm, malignant	0	0.0%	1	7.7%	1	3.1%
8070 Squamous cell carcinoma, NOS	8	42.1%	1	7.7%	9	28.1%
8140 Adenocarcinoma, NOS	2	10.5%	4	30.8%	6	18.8%
8200 Adenoid cystic carcinoma	4	21.1%	3	23.1%	7	21.9%
8430 Mucoepidermoid carcinoma	1	5.3%	3	23.1%	4	12.5%
8500 Infiltrating duct carcinoma, NOS	1	5.3%	1	7.7%	2	6.3%
8940 Mixed tumour, malignant, NOS	1	5.3%	0	0.0%	1	3.1%
8980 Carcinosarcoma, NOS	1	5.3%	0	0.0%	1	3.1%
9650 Hodgkin lymphoma, NOS	1	5.3%	0	0.0%	1	3.1%
Total	19	100.0%	13	100.0%	32	100.0%
C09 Tonsil	**No**	**%**	**No**	**%**	**No**	**%**
8000 Neoplasm, malignant	2	1.5%	1	4.3%	3	1.9%
8010 Carcinoma, NOS	2	1.5%	0	0.0%	2	1.3%

Site and histology	Male		Female		Total	
8070 Squamous cell carcinoma, NOS	114	87.0%	16	69.6%	130	84.4%
8140 Adenocarcinoma, NOS	0	0.0%	1	4.3%	1	0.6%
8430 Mucoepidermoid carcinoma	2	1.5%	0	0.0%	2	1.3%
9590 Malignant lymphoma, NOS	0	0.0%	1	4.3%	1	0.6%
9591 Malignant lymphoma, non-Hodgkin, NOS	5	3.8%	0	0.0%	5	3.2%
9650 Hodgkin lymphoma, NOS	1	0.8%	0	0.0%	1	0.6%
9670 Malignant lymphoma, small B lymphocytic, NOS	0	0.0%	1	4.3%	1	0.6%
9680 Malignant lymphoma, large B-cell, diffuse, NOS	3	2.3%	2	8.7%	5	3.2%
9687 Burkitt lymphoma, NOS	1	0.8%	0	0.0%	1	0.6%
9690 Follicular lymphoma, NOS	1	0.8%	0	0.0%	1	0.6%
9699 Marginal zone B-cell lymphoma, NOS	0	0.0%	1	4.3%	1	0.6%
Total	**131**	**100.0%**	**23**	**100.0%**	**154**	**100.0%**
C10 Oropharynx	**No**	**%**	**No**	**%**	**No**	**%**
8000 Neoplasm, malignant	5	5.8%	0	0.0%	5	5.4%
8010 Carcinoma, NOS	3	3.5%	1	16.7%	4	4.3%
8070 Squamous cell carcinoma, NOS	76	88.4%	5	83.3%	81	88.1%
8075 Squamous cell carcinoma, adenoid	1	1.2%	0	0.0%	1	1.1%
8140 Adenocarcinoma, NOS	1	1.2%	0	0.0%	1	1.1%
Total	**86**	**100.0%**	**6**	**100.0%**	**92**	**100.0%**
C11 Nasopharynx	**No**	**%**	**No**	**%**	**No**	**%**
8000 Neoplasm, malignant	4	14.3%	3	25.0%	7	17.5%
8010 Carcinoma, NOS	6	21.4%	2	16.7%	8	20.0%
8020 Carcinoma, undifferentiated, NOS	0	0.0%	1	8.3%	1	2.5%
8070 Squamous cell carcinoma, NOS	14	50.0%	4	33.3%	18	45.0%
8072 Squamous cell carcinoma, large cell, nonkeratinizing.	2	7.1%	1	8.3%	3	7.5%
8480 Mucinous adenocarcinoma	1	3.6%	0	0.0%	1	2.5%
8910 Embryonal rhabdomyosarcoma, NOS	0	0.0%	1	8.3%	1	2.5%
9680 Malignant lymphoma, large B-cell, diffuse, NOS	1	3.6%	0	0.0%	1	2.5%
Total	28	**100.0%**	**12**	**100.0%**	**40**	**100.0%**
C12 Pyriform sinus	**No**	**%**	**No**	**%**	**No**	**%**
8000 Neoplasm, malignant	4	2.4%	0	0.0%	4	2.1%
8010 Carcinoma, NOS	2	1.2%	0	0.0%	2	1.1%
8070 Squamous cell carcinoma, NOS	161	95.3%	18	100.0%	179	95.7%
8071 Squamous cell carcinoma, keratinizing, NOS	2	1.2%	0	0.0%	2	1.1%
Total	**169**	**100.0%**	**18**	**100.0%**	**187**	**100.0%**
C13 Hypopharynx	**No**	**%**	**No**	**%**	**No**	**%**
8000 Neoplasm, malignant	0	0.0%	1	4.5%	1	2.1%
8070 Squamous cell carcinoma, NOS	26	100.0%	21	95.5%	47	97.9%
Total	**26**	**100.0%**	**22**	**100.0%**	**48**	**100.0%**
C14 Other and ill-defined sites in lip, oral cavity and pharynx	**No**	**%**	**No**	**%**	**No**	**%**
8000 Neoplasm, malignant	1	1.7%	1	3.6%	2	2.3%
8010 Carcinoma, NOS	3	5.1%	1	3.6%	4	4.6%
8070 Squamous cell carcinoma, NOS	52	88.1%	23	82.1%	75	86.2%
8071 Squamous cell carcinoma, keratinizing, NOS	0	0.0%	1	3.6%	1	1.1%
8075 Squamous cell carcinoma, adenoid	1	1.7%	0	0.0%	1	1.1%
8200 Adenoid cystic carcinoma	1	1.7%	1	3.6%	2	2.3%
8430 Mucoepidermoid carcinoma	0	0.0%	1	3.6%	1	1.1%
9651 Hodgkin lymphoma, lymphocyte-rich	1	1.7%	0	0.0%	1	1.1%
Total	**59**	**100.0%**	**28**	**100.0%**	**87**	**100.0%**
C15 Oesophagus	**No**	**%**	**No**	**%**	**No**	**%**
8000 Neoplasm, malignant	41	7.1%	29	5.8%	70	6.5%
8010 Carcinoma, NOS	12	2.1%	10	2.0%	22	2.1%

Site and histology	Male		Female		Total	
8070 Squamous cell carcinoma, NOS	428	74.6%	415	83.7%	843	78.8%
8071 Squamous cell carcinoma, keratinizing, NOS	2	0.3%	3	0.6%	5	0.5%
8072 Squamous cell carcinoma, large cell, nonkeratinizing.	0	0.0%	2	0.4%	2	0.2%
8074 Squamous cell carcinoma, spindle cell	0	0.0%	1	0.2%	1	0.1%
8083 Basaloid squamous cell carcinoma	0	0.0%	2	0.4%	2	0.2%
8140 Adenocarcinoma, NOS	87	15.2%	31	6.3%	118	11.0%
8430 Mucoepidermoid carcinoma	0	0.0%	1	0.2%	1	0.1%
8480 Mucinous adenocarcinoma	0	0.0%	1	0.2%	1	0.1%
8490 Signet ring cell carcinoma	4	0.7%	0	0.0%	4	0.4%
8560 Adenosquamous carcinoma	0	0.0%	1	0.2%	1	0.1%
Total	**574**	**100.0%**	**496**	**100.0%**	**1070**	**100.0%**
C16 Stomach	**No**	**%**	**No**	**%**	**No**	**%**
8000 Neoplasm, malignant	23	10.2%	8	8.2%	31	9.6%
8004 Malignant tumour, spindle cell type	0	0.0%	1	1.0%	1	0.3%
8010 Carcinoma, NOS	9	4.0%	3	3.1%	12	3.7%
8032 Spindle cell carcinoma, NOS	1	0.4%	1	1.0%	2	0.6%
8070 Squamous cell carcinoma, NOS	14	6.2%	11	11.3%	25	7.7%
8072 Squamous cell carcinoma, large cell, nonkeratinizing	0	0.0%	1	1.0%	1	0.3%
8140 Adenocarcinoma, NOS	139	61.5%	52	53.6%	191	59.1%
8142 Linitis plastica	1	0.4%	0	0.0%	1	0.3%
8144 Adenocarcinoma, intestinal type	9	4.0%	0	0.0%	9	2.8%
8145 Carcinoma, diffuse type	0	0.0%	1	1.0%	1	0.3%
8246 Neuroendocrine carcinoma, NOS	1	0.4%	0	0.0%	1	0.3%
8260 Papillary adenocarcinoma, NOS	0	0.0%	2	2.1%	2	0.6%
8480 Mucinous adenocarcinoma	3	1.3%	1	1.0%	4	1.2%
8481 Mucin-producing adenocarcinoma	1	0.4%	0	0.0%	1	0.3%
8490 Signet ring cell carcinoma	19	8.4%	8	8.2%	27	8.4%
8936 Gastrointestinal stromal sarcoma	5	2.2%	7	7.2%	12	3.7%
9591 Malignant lymphoma, non-Hodgkin, NOS	1	0.4%	0	0.0%	1	0.3%
9699 Marginal zone B-cell lymphoma, NOS	0	0.0%	1	1.0%	1	0.3%
Total	**226**	**100.0%**	**97**	**100.0%**	**323**	**100.0%**
C17 Small intestine	**No**	**%**	**No**	**%**	**No**	**%**
8000 Neoplasm, malignant	0	0.0%	1	5.3%	1	2.4%
8010 Carcinoma, NOS	2	9.1%	0	0.0%	2	4.9%
8140 Adenocarcinoma, NOS	10	45.5%	11	57.9%	21	51.2%
8240 Carcinoid tumour, NOS	2	9.1%	1	5.3%	3	7.3%
8260 Papillary adenocarcinoma, NOS	0	0.0%	1	5.3%	1	2.4%
8936 Gastrointestinal stromal sarcoma	3	13.6%	3	15.8%	6	14.6%
9591 Malignant lymphoma, non-Hodgkin, NOS	1	4.5%	1	5.3%	2	4.9%
9670 Malignant lymphoma, small B lymphocytic, NOS	1	4.5%	0	0.0%	1	2.4%
9680 Malignant lymphoma, large B-cell, diffuse, NOS	3	13.6%	0	0.0%	3	7.3%
9687 Burkitt lymphoma, NOS	0	0.0%	1	5.3%	1	2.4%
Total	**22**	**100.0%**	**19**	**100.0%**	**41**	**100.0%**
C18 Colon	**No**	**%**	**No**	**%**	**No**	**%**
8000 Neoplasm, malignant	8	3.6%	12	5.4%	20	4.5%
8010 Carcinoma, NOS	2	0.9%	3	1.4%	5	1.1%
8050 Papillary carcinoma, NOS	1	0.5%	0	0.0%	1	0.2%
8070 Squamous cell carcinoma, NOS	1	0.5%	0	0.0%	1	0.2%
8071 Squamous cell carcinoma, keratinizing, NOS	1	0.5%	0	0.0%	1	0.2%
8140 Adenocarcinoma, NOS	181	81.9%	192	86.5%	373	84.2%
8240 Carcinoid tumour, NOS	2	0.9%	0	0.0%	2	0.5%
8246 Neuroendocrine carcinoma, NOS	0	0.0%	1	0.5%	1	0.2%

Site and histology	Male		Female		Total	
8263 Adenocarcinoma in tubulovillous adenoma	2	0.9%	0	0.0%	2	0.5%
8480 Mucinous adenocarcinoma	18	8.1%	8	3.6%	26	5.9%
8481 Mucin-producing adenocarcinoma	0	0.0%	2	0.9%	2	0.5%
8490 Signet ring cell carcinoma	1	0.5%	3	1.4%	4	0.9%
8936 Gastrointestinal stromal sarcoma	1	0.5%	0	0.0%	1	0.2%
9591 Malignant lymphoma, non-Hodgkin, NOS	1	0.5%	1	0.5%	2	0.5%
9687 Burkitt lymphoma, NOS	1	0.5%	0	0.0%	1	0.2%
9699 Marginal zone B-cell lymphoma, NOS	1	0.5%	0	0.0%	1	0.2%
Total	**221**	**100.0%**	**222**	**100.0%**	**443**	**100.0%**
C19 Rectosigmoid junction	**No**	**%**	**No**	**%**	**No**	**%**
8000 Neoplasm, malignant	1	3.3%	4	8.7%	5	6.6%
8010 Carcinoma, NOS	0	0.0%	1	2.2%	1	1.3%
8070 Squamous cell carcinoma, NOS	1	3.3%	0	0.0%	1	1.3%
8140 Adenocarcinoma, NOS	26	86.7%	39	84.8%	65	85.5%
8246 Neuroendocrine carcinoma, NOS	1	3.3%	0	0.0%	1	1.3%
8480 Mucinous adenocarcinoma	0	0.0%	2	4.3%	2	2.6%
8481 Mucin-producing adenocarcinoma	1	3.3%	0	0.0%	1	1.3%
Total	**30**	**100.0%**	**46**	**100.0%**	**76**	**100.0%**
C20 Rectum	**No**	**%**	**No**	**%**	**No**	**%**
8000 Neoplasm, malignant	15	4.7%	10	4.0%	25	4.4%
8004 Malignant tumour, spindle cell type	0	0.0%	1	0.4%	1	0.2%
8010 Carcinoma, NOS	1	0.3%	1	0.4%	2	0.4%
8070 Squamous cell carcinoma, NOS	8	2.5%	4	1.6%	12	2.1%
8140 Adenocarcinoma, NOS	271	85.8%	218	87.9%	489	86.7%
8210 Adenocarcinoma in adenomatous polyp	0	0.0%	1	0.4%	1	0.2%
8240 Carcinoid tumour, NOS	0	0.0%	1	0.4%	1	0.2%
8246 Neuroendocrine carcinoma, NOS	0	0.0%	1	0.4%	1	0.2%
8263 Adenocarcinoma in tubulovillous adenoma	1	0.3%	0	0.0%	1	0.2%
8480 Mucinous adenocarcinoma	8	2.5%	6	2.4%	14	2.5%
8481 Mucin-producing adenocarcinoma	1	0.3%	1	0.4%	2	0.4%
8490 Signet ring cell carcinoma	5	1.6%	2	0.8%	7	1.2%
8560 Adenosquamous carcinoma	0	0.0%	1	0.4%	1	0.2%
8720 Malignant melanoma, NOS	3	0.9%	0	0.0%	3	0.5%
8800 Sarcoma, NOS	1	0.3%	0	0.0%	1	0.2%
8936 Gastrointestinal stromal sarcoma	2	0.6%	0	0.0%	2	0.4%
9680 Malignant lymphoma, large B-cell, diffuse, NOS	0	0.0%	1	0.4%	1	0.2%
Total	**316**	**100.0%**	**248**	**100.0%**	**564**	**100.0%**
C21 Anus and anal canal	**No**	**%**	**No**	**%**	**No**	**%**
8000 Neoplasm, malignant	0	0.0%	2	9.1%	2	4.0%
8010 Carcinoma, NOS	1	3.6%	0	0.0%	1	2.0%
8070 Squamous cell carcinoma, NOS	18	64.3%	7	31.8%	25	50.0%
8123 Basaloid carcinoma	2	7.1%	1	4.5%	3	6.0%
8140 Adenocarcinoma, NOS	6	21.4%	11	50.0%	17	34.0%
8720 Malignant melanoma, NOS	0	0.0%	1	4.5%	1	2.0%
8800 Sarcoma, NOS	1	3.6%	0	0.0%	1	2.0%
Total	**28**	**100.0%**	**22**	**100.0%**	**50**	**100.0%**
C22 Liver and intrahepatic bile ducts	**No**	**%**	**No**	**%**	**No**	**%**
8000 Neoplasm, malignant	1	0.8%	0	0.0%	1	0.6%
8140 Adenocarcinoma, NOS	3	2.3%	2	5.3%	5	2.9%
8160 Cholangiocarcinoma	8	6.1%	3	7.9%	11	6.5%
8170 Hepatocellular carcinoma, NOS	117	88.6%	22	57.9%	139	81.8%
8806 Desmoplastic small round cell tumour	0	0.0%	1	2.6%	1	0.6%

Site and histology	Male		Female		Total	
8854 Pleomorphic liposarcoma	1	0.8%	0	0.0%	1	0.6%
8970 Hepatoblastoma	2	1.5%	7	18.4%	9	5.3%
9130 Hemangioendothelioma, malignant	0	0.0%	2	5.3%	2	1.2%
9670 Malignant lymphoma, small B lymphocytic, NOS	0	0.0%	1	2.6%	1	0.6%
Total	**132**	**100.0%**	**38**	**100.0%**	**170**	**100.0%**
C23 Gallbladder	**No**	**%**	**No**	**%**	**No**	**%**
8000 Neoplasm, malignant	2	20.0%	11	45.8%	13	38.2%
8070 Squamous cell carcinoma, NOS	0	0.0%	1	4.2%	1	2.9%
8140 Adenocarcinoma, NOS	7	70.0%	12	50.0%	19	55.9%
8260 Papillary adenocarcinoma, NOS	1	10.0%	0	0.0%	1	2.9%
Total	**10**	**100.0%**	**24**	**100.0%**	**34**	**100.0%**
C24 Other and unspecified parts of biliary tract	**No**	**%**	**No**	**%**	**No**	**%**
8000 Neoplasm, malignant	3	9.4%	3	12.5%	6	10.7%
8010 Carcinoma, NOS	0	0.0%	1	4.2%	1	1.8%
8140 Adenocarcinoma, NOS	11	34.4%	8	33.3%	19	33.9%
8160 Cholangiocarcinoma	18	56.3%	12	50.0%	30	53.6%
Total	**32**	**100.0%**	**24**	**100.0%**	**56**	**100.0%**
C25 Pancreas	**No**	**%**	**No**	**%**	**No**	**%**
8000 Neoplasm, malignant	14	30.4%	24	42.9%	38	37.3%
8010 Carcinoma, NOS	1	2.2%	3	5.4%	4	3.9%
8140 Adenocarcinoma, NOS	21	45.7%	19	33.9%	40	39.2%
8154 Mixed islet cell and exocrine adenocarcinoma	1	2.2%	1	1.8%	2	2.0%
8240 Carcinoid tumour, NOS	1	2.2%	0	0.0%	1	1.0%
8246 Neuroendocrine carcinoma, NOS	3	6.5%	0	0.0%	3	2.9%
8452 Solid pseudopapillary carcinoma	0	0.0%	1	1.8%	1	1.0%
8480 Mucinous adenocarcinoma	1	2.2%	1	1.8%	2	2.0%
8500 Infiltrating duct carcinoma, NOS	3	6.5%	2	3.6%	5	4.9%
8550 Acinar cell carcinoma	1	2.2%	3	5.4%	4	3.9%
8560 Adenosquamous carcinoma	0	0.0%	1	1.8%	1	1.0%
9590 Malignant lymphoma, NOS	0	0.0%	1	1.8%	1	1.0%
Total	**46**	**100.0%**	**56**	**100.0%**	**102**	**100.0%**
C26 Other and ill-defined digestive organs	**No**	**%**	**No**	**%**	**No**	**%**
8000 Neoplasm, malignant	1	7.7%	0	0.0%	1	4.5%
8010 Carcinoma, NOS	0	0.0%	1	11.1%	1	4.5%
8070 Squamous cell carcinoma, NOS	0	0.0%	1	11.1%	1	4.5%
8123 Basaloid carcinoma	1	7.7%	0	0.0%	1	4.5%
8140 Adenocarcinoma, NOS	3	23.1%	1	11.1%	4	18.2%
8480 Mucinous adenocarcinoma	1	7.7%	0	0.0%	1	4.5%
8490 Signet ring cell carcinoma	4	30.8%	1	11.1%	5	22.7%
8806 Desmoplastic small round cell tumour	0	0.0%	1	11.1%	1	4.5%
8936 Gastrointestinal stromal sarcoma	2	15.4%	4	44.4%	6	27.3%
9591 Malignant lymphoma, non-Hodgkin, NOS	1	7.7%	0	0.0%	1	4.5%
Total	**13**	**100.0%**	**9**	**100.0%**	**22**	**100.0%**
C30 Nasal cavity and middle ear	**No**	**%**	**No**	**%**	**No**	**%**
8070 Squamous cell carcinoma, NOS	12	52.2%	3	37.5%	15	48.4%
8140 Adenocarcinoma, NOS	1	4.3%	0	0.0%	1	3.2%
8200 Adenoid cystic carcinoma	3	13.0%	3	37.5%	6	19.4%
8720 Malignant melanoma, NOS	1	4.3%	1	12.5%	2	6.5%
8806 Desmoplastic small round cell tumour	1	4.3%	0	0.0%	1	3.2%
8900 Rhabdomyosarcoma, NOS	1	4.3%	0	0.0%	1	3.2%
9220 Chondrosarcoma, NOS	0	0.0%	1	12.5%	1	3.2%
9522 Olfactory neuroblastoma	2	8.7%	0	0.0%	2	6.5%

Site and histology	Male		Female		Total	
9680 Malignant lymphoma, large B-cell, diffuse, NOS	1	4.3%	0	0.0%	1	3.2%
9734 Plasmacytoma, extramedullary	1	4.3%	0	0.0%	1	3.2%
Total	**23**	**100.0%**	**8**	**100.0%**	**31**	**100.0%**
C31 Accessory sinuses	**No**	**%**	**No**	**%**	**No**	**%**
8000 Neoplasm, malignant	4	14.8%	0	0.0%	4	9.8%
8010 Carcinoma, NOS	3	11.1%	0	0.0%	3	7.3%
8070 Squamous cell carcinoma, NOS	14	51.9%	9	64.3%	23	56.1%
8072 Squamous cell carcinoma, large cell, nonkeratinizing	1	3.7%	0	0.0%	1	2.4%
8140 Adenocarcinoma, NOS	1	3.7%	0	0.0%	1	2.4%
8200 Adenoid cystic carcinoma	3	11.1%	3	21.4%	6	14.6%
8900 Rhabdomyosarcoma, NOS	0	0.0%	1	7.1%	1	2.4%
9591 Malignant lymphoma, non-Hodgkin, NOS	1	3.7%	1	7.1%	2	4.9%
Total	**27**	**100.0%**	**14**	**100.0%**	**41**	**100.0%**
C32 Larynx	**No**	**%**	**No**	**%**	**No**	**%**
8000 Neoplasm, malignant	9	2.3%	3	8.3%	12	2.9%
8010 Carcinoma, NOS	4	1.0%	2	5.6%	6	1.4%
8032 Spindle cell carcinoma, NOS	1	0.3%	0	0.0%	1	0.2%
8033 Pseudosarcomatous carcinoma	1	0.3%	0	0.0%	1	0.2%
8070 Squamous cell carcinoma, NOS	364	94.8%	28	77.8%	392	93.3%
8071 Squamous cell carcinoma, keratinizing, NOS	1	0.3%	0	0.0%	1	0.2%
8072 Squamous cell carcinoma, large cell, nonkeratinizing.	1	0.3%	1	2.8%	2	0.5%
8083 Basaloid squamous cell carcinoma	1	0.3%	0	0.0%	1	0.2%
8140 Adenocarcinoma, NOS	0	0.0%	2	5.6%	2	0.5%
8200 Adenoid cystic carcinoma	2	0.5%	0	0.0%	2	0.5%
Total	**384**	**100.0%**	**36**	**100.0%**	**420**	**100.0%**
C33 Trachea	**No**	**%**	**No**	**%**	**No**	**%**
8010 Carcinoma, NOS	1	20.0%			1	20.0%
8070 Squamous cell carcinoma, NOS	4	80.0%			4	80.0%
Total	**5**	**100.0%**			**5**	**100.0%**
C34 Bronchus and lung	**No**	**%**	**No**	**%**	**No**	**%**
8000 Neoplasm, malignant	159	19.9%	34	16.3%	193	19.1%
8010 Carcinoma, NOS	28	3.5%	6	2.9%	34	3.4%
8012 Large cell carcinoma, NOS	14	1.7%	3	1.4%	17	1.7%
8013 Large cell neuroendocrine carcinoma	1	0.1%	0	0.0%	1	0.1%
8021 Carcinoma, anaplastic, NOS	2	0.2%	0	0.0%	2	0.2%
8022 Pleomorphic carcinoma	1	0.1%	0	0.0%	1	0.1%
8033 Pseudosarcomatous carcinoma	1	0.1%	0	0.0%	1	0.1%
8041 Small cell carcinoma, NOS	39	4.9%	5	2.4%	44	4.4%
8045 Combined small cell carcinoma	2	0.2%	0	0.0%	2	0.2%
8046 Non-small cell carcinoma	122	15.2%	26	12.4%	148	14.7%
8070 Squamous cell carcinoma, NOS	252	31.5%	38	18.2%	290	28.7%
8071 Squamous cell carcinoma, keratinizing, NOS	3	0.4%	0	0.0%	3	0.3%
8072 Squamous cell carcinoma, large cell, nonkeratinizing.	1	0.1%	1	0.5%	2	0.2%
8140 Adenocarcinoma, NOS	152	19.0%	76	36.4%	228	22.6%
8240 Carcinoid tumour, NOS	1	0.1%	3	1.4%	4	0.4%
8246 Neuroendocrine carcinoma, NOS	2	0.2%	1	0.5%	3	0.3%
8249 A typical carcinoid tumour	0	0.0%	1	0.5%	1	0.1%
8250 Bronchiolo-alveolar adenocarcinoma, NOS	11	1.4%	5	2.4%	16	1.6%
8251 Alveolar adenocarcinoma	0	0.0%	1	0.5%	1	0.1%
8253 Bronchiolo-alveolar carcinoma, mucinous	0	0.0%	2	1.0%	2	0.2%
8260 Papillary adenocarcinoma, NOS	1	0.1%	3	1.4%	4	0.4%
8310 Clear cell adenocarcinoma, NOS	2	0.2%	0	0.0%	2	0.2%

Site and histology	Male		Female		Total	
8480 Mucinous adenocarcinoma	2	0.2%	1	0.5%	3	0.3%
8490 Signet ring cell carcinoma	0	0.0%	1	0.5%	1	0.1%
8800 Sarcoma, NOS	0	0.0%	1	0.5%	1	0.1%
8810 Fibrosarcoma, NOS	0	0.0%	1	0.5%	1	0.1%
8890 Leiomyosarcoma, NOS	1	0.1%	0	0.0%	1	0.1%
8900 Rhabdomyosarcoma, NOS	1	0.1%	0	0.0%	1	0.1%
9591 Malignant lymphoma, non-Hodgkin, NOS	1	0.1%	0	0.0%	1	0.1%
9650 Hodgkin lymphoma, NOS	1	0.1%	0	0.0%	1	0.1%
9750 Malignant histiocytosis	1	0.1%	0	0.0%	1	0.1%
Total	**801**	**100.0%**	**209**	**100.0%**	**1010**	**100.0%**
C37 Thymus	**No**	**%**	**No**	**%**	**No**	**%**
8000 Neoplasm, malignant	1	8.3%	2	22.2%	3	14.3%
8580 Thymoma, malignant, NOS	6	50.0%	2	22.2%	8	38.1%
8581 Thymoma, type A, malignant	1	8.3%	0	0.0%	1	4.8%
8582 Thymoma, type AB, malignant	1	8.3%	1	11.1%	2	9.5%
8584 Thymoma, type B2, malignant	0	0.0%	1	11.1%	1	4.8%
8585 Thymoma, type B3, malignant	1	8.3%	2	22.2%	3	14.3%
8586 Thymic carcinoma, NOS	1	8.3%	1	11.1%	2	9.5%
8588 Spindle epithelial tumour with thymus-like element	1	8.3%	0	0.0%	1	4.8%
Total	**12**	**100.0%**	**9**	**100.0%**	**21**	**100.0%**
C38 Heart, mediastinum and pleura	**No**	**%**	**No**	**%**	**No**	**%**
8000 Neoplasm, malignant	2	15.4%	1	16.7%	3	15.8%
8004 Malignant tumor, spindle cell type	0	0.0%	1	16.7%	1	5.3%
8806 Desmoplastic small round cell tumour	1	7.7%	0	0.0%	1	5.3%
9050 Mesothelioma, malignant	4	30.8%	3	50.0%	7	36.8%
9071 Yolk sac tumour	1	7.7%	0	0.0%	1	5.3%
9080 Teratoma, malignant, NOS	1	7.7%	0	0.0%	1	5.3%
9085 Mixed germ cell tumour	2	15.4%	0	0.0%	2	10.5%
9500 Neuroblastoma, NOS	1	7.7%	0	0.0%	1	5.3%
9540 Malignant peripheral nerve sheath tumour	0	0.0%	1	16.7%	1	5.3%
9650 Hodgkin lymphoma, NOS	1	7.7%	0	0.0%	1	5.3%
Total	**13**	**100.0%**	**6**	**100.0%**	**19**	**100.0%**
C40 Bones, joints and articular cartilage of limbs	**No**	**%**	**No**	**%**	**No**	**%**
8000 Neoplasm, malignant	1	2.3%	1	3.8%	2	2.9%
9180 Osteosarcoma, NOS	25	56.8%	12	46.2%	37	52.9%
9181 Chondroblastic osteosarcoma	2	4.5%	0	0.0%	2	2.9%
9185 Small cell osteosarcoma	0	0.0%	1	3.8%	1	1.4%
9193 Periosteal osteosarcoma	0	0.0%	1	3.8%	1	1.4%
9220 Chondrosarcoma, NOS	2	4.5%	1	3.8%	3	4.3%
9231 Myxoid chondrosarcoma	1	2.3%	0	0.0%	1	1.4%
9240 Mesenchymal chondrosarcoma	0	0.0%	1	3.8%	1	1.4%
9250 Giant cell tumour of bone, malignant	2	4.5%	1	3.8%	3	4.3%
9260 Ewing sarcoma	8	18.2%	8	30.8%	16	22.9%
9731 Plasmacytoma, NOS	3	6.8%	0	0.0%	3	4.3%
Total	**44**	**100.0%**	**26**	**100.0%**	**70**	**100.0%**
C41 Bones, joints and articular cartilage of other and unspecified sites	**No**	**%**	**No**	**%**	**No**	**%**
8000 Neoplasm, malignant	2	7.7%	1	3.6%	3	5.6%
9180 Osteosarcoma, NOS	5	19.2%	7	25.0%	12	22.2%
9184 Osteosarcoma in Paget disease of bone	1	3.8%	0	0.0%	1	1.9%
9186 Central osteosarcoma	1	3.8%	0	0.0%	1	1.9%
9220 Chondrosarcoma, NOS	7	29.6%	4	14.3%	11	20.4%

Site and histology	Male		Female		Total	
9240 Mesenchymal chondrosarcoma	0	0.0%	1	3.6%	1	1.9%
9260 Ewing sarcoma	7	25.9%	10	35.7%	17	31.5%
9270 Odontogenic tumour, malignant	0	0.0%	2	7.1%	2	3.7%
9310 Ameloblastoma, malignant	0	0.0%	1	3.6%	1	1.9%
9370 Chordoma, NOS	0	0.0%	1	3.6%	1	1.9%
9731 Plasmacytoma, NOS	3	11.5%	1	3.6%	4	7.4%
Total	**26**	**100.0%**	**28**	**100.0%**	**54**	**100.0%**
C42 Hematopoietic and reticuloendothelial systems	**No**	**%**	**No**	**%**	**No**	**%**
9120 Hemangiosarcoma	0	0.0%	1	0.2%	1	0.1%
9590 Malignant lymphoma, NOS	4	0.7%	2	0.4%	6	0.6%
9591 Malignant lymphoma, non-Hodgkin, NOS	9	1.6%	11	2.2%	20	1.9%
9650 Hodgkin lymphoma, NOS	1	0.2%	1	0.2%	2	0.2%
9680 Malignant lymphoma, large B-cell, diffuse, NOS	1	0.2%	0	0.0%	1	0.1%
9689 Splenic marginal zone B-cell lymphoma	0	0.0%	1	0.2%	1	0.1%
9690 Follicular lymphoma, NOS	1	0.2%	1	0.2%	2	0.2%
9691 Folliculat lymphoma, grade 2	1	0.2%	0	0.0%	1	0.1%
9727 Precursor cell lymphoblastic lymphoma, NOS	1	0.2%	0	0.0%	1	0.1%
9731 Plasmacytoma, NOS	3	0.5%	1	0.2%	4	0.4%
9732 Multiple myeloma	117	21.1%	117	23.4%	234	22.2%
9733 Plasma cell leukaemia	3	0.5%	3	0.6%	6	0.6%
9754 Langerhans cell histiocytosis, disseminated	1	0.2%	0	0.0%	1	0.1%
9800 Leukaemia, NOS	0	0.0%	1	0.2%	1	0.1%
9801 Acute leukaemia, NOS	3	0.5%	1	0.2%	4	0.4%
9820 Lymphoid leukaemia, NOS	2	0.4%	1	0.2%	3	0.3%
9823 B-cell chronic lymphocytic leukaemia/small lymphocytic lymphoma	25	4.5%	14	2.8%	39	3.7%
9826 Burkitt cell leukaemia	0	0.0%	3	0.6%	3	0.3%
9835 Precursor cell lymphoblastic leukaemia, NOS	127	22.9%	88	17.6%	215	20.4%
9836 Precursor B-cell lymphoblastic leukaemia	10	1.8%	8	1.6%	18	1.7%
9837 Precursor T-cell lymphoblastic leukaemia	4	0.7%	2	0.4%	6	0.6%
9840 Acute myeloid leukaemia, M6 type	1	0.2%	1	0.2%	2	0.2%
9861 Acute myeloid leukaemia, NOS	44	7.9%	47	9.4%	91	8.6%
9863 Chronic myeloid leukaemia, NOS	74	13.3%	51	10.2%	125	11.9%
9866 Acute promyelocytic leukaemia, t(15;17)(q22;q11-12)	13	2.3%	17	3.4%	30	2.8%
9867 Acute myelomonocytic leukaemia	12	2.2%	13	2.6%	25	2.4%
9872 Acute myeloid leukaemia, minimal differentiation	0	0.0%	2	0.4%	2	0.2%
9873 Acute myeloid leukaemia without maturation	5	0.9%	5	1.0%	10	0.9%
9874 Acute myeloid leukaemia with maturation	24	4.3%	23	4.6%	47	4.5%
9875 Chronic myelogenous leukaemia, BCR/ABL positive	2	0.4%	5	1.0%	7	0.7%
9891 Acute monocytic leukaemia	3	0.5%	1	0.2%	4	0.4%
9910 Acute megakaryoblastic leukaemia	1	0.2%	4	0.8%	5	0.5%
9931 Acute panmyelosis with myelofibrosis	11	2.0%	5	1.0%	16	1.5%
9940 Hairy cell leukaemia	1	0.2%	1	0.2%	2	0.2%
9945 Chronic myelomonocytic leukaemia, NOS	1	0.2%	0	0.0%	1	0.1%
9946 Juvenile myelomonocytic leukaemia	2	0.4%	1	0.2%	3	0.3%
9950 Polycythemia vera	8	1.4%	0	0.0%	8	0.8%
9960 Chronic myeloproliferative disease, NOS	1	0.2%	4	0.8%	5	0.5%
9961 Myelosclerosis with myeloid metaplasia	3	0.5%	2	0.4%	5	0.5%
9962 Essential thrombocythemia	1	0.2%	2	0.4%	3	0.3%
9964 Hypereosinophilic syndrome	1	0.2%	0	0.0%	1	0.1%
9980 Refractory anaemia	2	0.4%	3	0.6%	5	0.5%
9982 Refractory anaemia with sideroblasts	1	0.2%	0	0.0%	1	0.1%

Site and histology	Male		Female		Total	
9983 Refractory anaemia with excess blasts	0	0.0%	1	0.2%	1	0.1%
9989 Myelodysplastic syndrome, NOS	31	5.6%	55	11.0%	86	8.2%
Total	**555**	**100.0%**	**499**	**100.0%**	**1054**	**100.0%**
C44 Skin	**No**	**%**	**No**	**%**	**No**	**%**
8000 Neoplasm, malignant	3	1.9%	2	1.4%	5	1.7%
8004 Malignant tumor, spindle cell type	0	0.0%	1	0.7%	1	0.3%
8010 Carcinoma, NOS	1	0.6%	1	0.7%	2	0.7%
8032 Spindle cell carcinoma, NOS	1	0.6%	1	0.7%	2	0.7%
8051 Verrucous carcinoma, NOS	3	1.9%	1	0.7%	4	1.3%
8070 Squamous cell carcinoma, NOS	76	48.1%	49	34.8%	125	41.8%
8071 Squamous cell carcinoma, keratinizing, NOS	1	0.6%	1	0.7%	2	0.7%
8075 Squamous cell carcinoma, adenoid	1	0.6%	1	0.7%	2	0.7%
8083 Basaloid squamous cell carcinoma	1	0.6%	0	0.0%	1	0.3%
8090 Basal cell carcinoma, NOS	10	6.3%	27	19.1%	37	12.4%
8091 Multifocal superficial basal cell carcinoma	0	0.0%	1	0.7%	1	0.3%
8094 Basosquamous carcinoma	2	1.3%	2	1.4%	4	1.3%
8097 Basal cell carcinoma, nodular	3	1.9%	3	2.1%	6	2.0%
8140 Adenocarcinoma, NOS	0	0.0%	1	0.7%	1	0.3%
8200 Adenoid cystic carcinoma	1	0.6%	0	0.0%	1	0.3%
C44 Skin	**No**	**%**	**No**	**%**	**No**	**%**
8390 Skin appendage carcinoma	1	0.6%	2	1.4%	3	1.0%
8401 Apocrine adenocarcinoma	1	0.6%	0	0.0%	1	0.3%
8409 Eccrine poroma, malignant	0	0.0%	1	0.7%	1	0.3%
8410 Sebaceous adenocarcinoma	5	3.2%	2	1.4%	7	2.3%
8430 Mucoepidermoid carcinoma	0	0.0%	2	1.4%	2	0.7%
8720 Malignant melanoma, NOS	36	22.8%	22	15.6%	58	19.4%
8721 Nodular melanoma	1	0.6%	3	2.1%	4	1.3%
8742 Lentigomaligna melanoma	0	0.0%	1	0.7%	1	0.3%
8771 Epitheliod cell melanoma	0	0.0%	1	0.7%	1	0.3%
8772 Spindle cell melanoma, NOS	1	0.6%	0	0.0%	1	0.3%
8832 Dermatofibrosarcoma, NOS	6	3.8%	3	2.1%	9	3.0%
8940 Mixed tumor, malignant, NOS	0	0.0%	1	0.7%	1	0.3%
9130 Hemangioendothelioma, malignant	0	0.0%	1	0.7%	1	0.3%
9150 Hemangiopericytoma, malignant	0	0.0%	1	0.7%	1	0.3%
9591 Malignant lymphoma, non-Hodgkin, NOS	1	0.6%	3	2.1%	4	1.3%
9700 Mycosis fungoides	2	1.3%	3	2.1%	5	1.7%
9708 Subcutaneous panniculitis-like T-cell lymphoma	0	0.0%	1	0.7%	1	0.3%
9709 Cutaneous T-cell lymphoma, NOS	1	0.6%	3	2.1%	4	1.3%
Total	**158**	**100.0%**	**141**	**100.0%**	**299**	**100.0%**
C47 Peripheral nerves and autonomic nervous system	**No**	**%**	**No**	**%**	**No**	**%**
9364 Peripheral neuroectodermal tumour	2	20.0%	0	0.0%	2	13.3%
9490 Ganglioneuroblastoma	0	0.0%	1	20.0%	1	6.7%
9500 Neuroblastoma, NOS	3	30.0%	0	0.0%	3	20.0%
9540 Malignant peripheral nerve sheath tumour	5	50.0%	4	80.0%	9	60.0%
Total	**10**	**100.0%**	**5**	**100.0%**	**15**	**100.0%**
C48 Retroperitoneum and peritoneum	**No**	**%**	**No**	**%**	**No**	**%**
8000 Neoplasm, malignant	2	33.3%	5	17.2%	7	20.0%
8004 Malignant tumour, spindle cell type	2	33.3%	1	3.4%	3	8.6%
8461 Serous surface papillary carcinoma	0	0.0%	3	10.3%	3	8.6%
8800 Sarcoma, NOS	0	0.0%	3	10.3%	3	8.6%
8801 Spindle celll sarcoma	0	0.0%	1	3.4%	1	2.9%
8811 Fibromyxosarcoma	0	0.0%	2	6.9%	2	5.7%

Site and histology	Male		Female		Total	
8850 Liposarcoma, NOS	1	16.7%	4	13.8%	5	14.3%
8852 Myxoid liposarcoma	0	0.0%	1	3.4%	1	2.9%
8890 Leiomyosarcoma, NOS	1	16.7%	4	13.8%	5	14.3%
9052 Epithelioid mesothelioma, malignant	0	0.0%	1	3.4%	1	2.9%
9080 Teratoma, malignant, NOS	0	0.0%	3	10.3%	3	8.6%
9500 Neuroblastoma, NOS	0	0.0%	1	3.4%	1	2.9%
Total	**6**	**100.0%**	**29**	**100.0%**	**35**	**100.0%**
C49 Connective, subcutaneous and other soft tissues	**No**	**%**	**No**	**%**	**No**	**%**
8000 Neoplasm, malignant	2	2.0%	0	0.0%	2	1.3%
8004 Malignant tumour, spindle cell type	7	7.1%	0	0.0%	7	4.4%
8800 Sarcoma, NOS	21	21.4%	7	11.9%	28	17.6%
8801 Spindle cell sarcoma	8	8.2%	6	10.2%	14	8.8%
8802 Giant cell sarcoma	2	2.0%	2	3.4%	4	2.5%
8803 Small cell sarcoma	1	1.0%	0	0.0%	1	0.6%
8806 Desmoplastic small round cell tumour	3	3.0%	3	5.1%	6	3.8%
8810 Fibrosarcoma, NOS	2	2.0%	1	1.7%	3	1.9%
8811 Fibromyxosarcoma	2	2.0%	3	5.1%	5	3.1%
8830 Malignant fibrous histiocytoma	3	3.1%	5	8.5%	8	5.0%
8840 Myxosarcoma	1	1.0%	0	0.0%	1	0.6%
8850 Liposarcoma, NOS	6	6.1%	4	6.8%	10	6.3%
8852 Myxoid liposarcoma	0	0.0%	2	3.4%	2	1.3%
8890 Leiomyosarcoma, NOS	6	6.1%	6	10.2%	12	7.5%
8900 Rhabdomyosarcoma, NOS	3	3.1%	3	5.1%	6	3.8%
8901 Pleomorphic rhabdomyosarcoma, adult type	2	2.0%	0	0.0%	2	1.3%
8910 Embryonal rhabdomyosarcoma, NOS	3	3.1%	2	3.4%	5	3.1%
8920 Alveolar rhabdomyosarcoma	2	2.0%	0	0.0%	2	1.3%
9040 Synovial sarcoma, NOS	6	6.1%	5	8.5%	11	6.9%
9041 Synovial sarcoma, spindle cell	2	2.0%	1	1.7%	3	1.9%
9043 Synovial sarcoma, biphasic	3	3.1%	2	3.4%	5	3.1%
9120 Hemangiosarcoma	2	2.0%	1	1.7%	3	1.9%
9130 Hemangioendothelioma, malignant	1	1.0%	0	0.0%	1	0.6%
9150 Hemangiopericytoma, malignant	1	1.0%	1	1.7%	2	1.3%
9364 Peripheral neuroectodermal tumour	2	2.0%	0	0.0%	2	1.3%
9365 Askin tumour	1	1.0%	0	0.0%	1	0.6%
9734 Plasmacytoma, extramedullary	2	2.0%	0	0.0%	2	1.3%
9750 Malignant histiocytosis	0	0.0%	1	1.7%	1	0.6%
9751 Langerhan's cell histiocytosis, NOS	1	1.0%	0	0.0%	1	0.6%
9754 Langerhans cell histiocytosis, disseminated	3	3.1%	2	3.4%	5	3.1%
9930 Myeloid sarcoma	1	1.0%	2	3.4%	3	1.9%
Total	**99**	**100.0%**	**59**	**100.0%**	**158**	**100.0%**
C50 Breast	**No**	**%**	**No**	**%**	**No**	**%**
8000 Neoplasm, malignant	2	5.1%	118	4.9%	120	4.9%
8010 Carcinoma, NOS	2	5.1%	28	1.2%	30	1.2%
8022 Pleomorphic carcinoma	0	0.0%	1	0.0%	1	0.0%
8032 Spindle cell carcinoma, NOS	0	0.0%	2	0.1%	2	0.1%
8033 Pseudosarcomatous carcinoma	0	0.0%	1	0.0%	1	0.0%
8050 Papillary carcinoma, NOS	0	0.0%	6	0.2%	6	0.2%
8070 Squamous cell carcinoma, NOS	0	0.0%	1	0.0%	1	0.0%
8140 Adenocarcinoma, NOS	1	2.6%	10	0.4%	11	0.5%
8200 Adenoid cystic carcinoma	0	0.0%	1	0.0%	1	0.0%
8201 Cribriform carcinoma, NOS	0	0.0%	4	0.2%	4	0.2%
8211 Tubular adenocarcinoma	0	0.0%	1	0.0%	1	0.0%

Site and histology	Male		Female		Total	
8260 Papillary adenocarcinoma, NOS	0	0.0%	5	0.2%	5	0.2%
8480 Mucinous adenocarcinoma	0	0.0%	21	0.9%	21	0.9%
8500 Infiltrating duct carcinoma, NOS	33	84.6%	2086	86.9%	2119	86.8%
8501 Comedocarcinoma, NOS	0	0.0%	3	0.1%	3	0.1%
8502 Secretory carcinoma of breast	1	2.6%	0	0.0%	1	0.0%
8503 Intraductal papillary adenocarcinoma with invasion	0	0.0%	2	0.1%	2	0.1%
8504 Intracystic carcinoma, NOS	0	0.0%	3	0.1%	3	0.1%
8510 Medullary carcinoma, NOS	0	0.0%	8	0.3%	8	0.3%
8520 Lobular carcinoma, NOS	0	0.0%	55	2.3%	55	2.3%
8521 Infiltrating ductular carcinoma	0	0.0%	1	0.0%	1	0.0%
8522 Infiltrating duct and lobular carcinoma	0	0.0%	6	0.2%	6	0.2%
8523 Infiltrating duct mixed with other types of carcinoma	0	0.0%	3	0.1%	3	0.1%
8524 Infiltrating lobular mixed with other types of carcinoma	0	0.0%	2	0.1%	2	0.1%
8530 Inflammatory carcinoma	0	0.0%	2	0.1%	2	0.1%
8540 Paget disease, mammary	0	0.0%	8	0.3%	8	0.3%
8560 Adenosquamous carcinoma	0	0.0%	1	0.0%	1	0.0%
8574 Adenocarcinoma with neuroendocrine differenciation	0	0.0%	4	0.2%	4	0.2%
8575 Metaplastic carcinoma, NOS	0	0.0%	3	0.1%	3	0.1%
8800 Sarcoma, NOS	0	0.0%	1	0.0%	1	0.0%
8890 Leiomyosarcoma, NOS	0	0.0%	2	0.1%	2	0.1%
8935 Stromal sarcoma, NOS	0	0.0%	1	0.0%	1	0.0%
8980 Carcinosarcoma, NOS	0	0.0%	2	0.1%	2	0.1%
9020 Phyllodes tumour, malignant	0	0.0%	5	0.2%	5	0.2%
9120 Hemangiosarcoma	0	0.0%	3	0.1%	3	0.1%
9702 Mature T-cell lymphoma, NOS	0	0.0%	1	0.0%	1	0.0%
Total	**39**	**100.0%**	**2401**	**100.0%**	**2440**	**100.0%**
C51 Vulva	**No**	**%**	**No**	**%**	**No**	**%**
8000 Neoplasm, malignant			1	2.9%	1	2.9%
8070 Squamous cell carcinoma, NOS			25	71.4%	25	71.4%
8071 Squamous cell carcinoma, keratinizing, NOS			2	5.7%	2	5.7%
8072 Squamous cell carcinoma, large cell, nonkeratin			2	5.7%	2	5.7%
8090 Basal cell carcinoma, NOS			1	2.9%	1	2.9%
8123 Basaloid carcinoma			1	2.9%	1	2.9%
8200 Adenoid cystic carcinoma			1	2.9%	1	2.9%
8720 Malignant melanoma, NOS			1	2.9%	1	2.9%
8730 Amelanotic melanoma			1	2.9%	1	2.9%
Total			**35**	**100.0%**	**35**	**100.0%**
C52 Vagina	**No**	**%**	**No**	**%**	**No**	**%**
8000 Neoplasm, malignant			2	8.7%	2	8.7%
8070 Squamous cell carcinoma, NOS			15	65.2%	15	65.2%
8071 Squamous cell carcinoma, keratinizing, NOS			1	4.3%	1	4.3%
8072 Squamous cell carcinoma, large cell, nonkeratin			2	8.7%	2	8.7%
8083 Basaloid squamous cell carcinoma			1	4.3%	1	4.3%
8140 Adenocarcinoma, NOS			2	8.7%	2	8.7%
Total			**23**	**100.0%**	**23**	**100.0%**
C53 Cervix uteri	**No**	**%**	**No**	**%**	**No**	**%**
8000 Neoplasm, malignant			45	5.3%	45	5.3%
8010 Carcinoma, NOS			18	2.1%	18	2.1%
8070 Squamous cell carcinoma, NOS			538	63.5%	538	63.5%
8071 Squamous cell carcinoma, keratinizing, NOS			73	8.6%	73	8.6%
8072 Squamous cell carcinoma, large cell, nonkeratin			137	16.2%	137	16.2%
8073 Squamous cell carcinoma, small cell, nonkeratin			4	0.5%	4	0.5%

Site and histology	Male		Female		Total	
8076 Squamous cell carcinoma, microinvasive			1	0.1%	1	0.1%
8083 Basaloid squamous cell carcinoma			1	0.1%	1	0.1%
8098 Adenoid basal carcinoma			1	0.1%	1	0.1%
8140 Adenocarcinoma, NOS			23	2.7%	23	2.7%
8260 Papillary adenocarcinoma, NOS			2	0.2%	2	0.2%
8480 Mucinous adenocarcinoma			1	0.1%	1	0.1%
8481 Mucin-producing adenocarcinoma			1	0.1%	1	0.1%
8560 Adenosquamous carcinoma			2	0.2%	2	0.2%
Total			**847**	**100.0%**	**847**	**100.0%**
C54 Corpus uteri	**No**	**%**	**No**	**%**	**No**	**%**
8000 Neoplasm, malignant			10	3.0%	10	3.0%
8010 Carcinoma, NOS			2	0.6%	2	0.6%
8070 Squamous cell carcinoma, NOS			9	2.7%	9	2.7%
8071 Squamous cell carcinoma, keratinizing, NOS			1	0.3%	1	0.3%
8072 Squamous cell carcinoma, large cell, nonkeratin			1	0.3%	1	0.3%
8140 Adenocarcinoma, NOS			114	34.5%	114	34.5%
8260 Papillary adenocarcinoma, NOS			4	1.2%	4	1.2%
8310 Clear cell adenocarcinoma, NOS			5	1.5%	5	1.5%
8380 Endometrioid adenocarcinoma, NOS			162	49.1%	162	49.1%
8460 Papillary serous cystadenocarcinoma			2	0.6%	2	0.6%
8800 Sarcoma, NOS			2	0.6%	2	0.6%
8890 Leiomyosarcoma, NOS			1	0.3%	1	0.3%
8930 Endometrial stromal sarcoma, NOS			10	3.0%	10	3.0%
8933 Adenosarcoma			4	1.2%	4	1.2%
8950 Mullerian mixed tumour			1	0.3%	1	0.3%
8980 Carcinosarcoma, NOS			2	0.6%	2	0.6%
Total			**330**	**100.0%**	**330**	**100.0%**
C55 Uterus, NOS	**No**	**%**	**No**	**%**	**No**	**%**
8010 Carcinoma, NOS			1	1.8%	1	1.8%
8041 Small cell carcinoma, NOS			1	1.8%	1	1.8%
8070 Squamous cell carcinoma, NOS			5	8.9%	5	8.9%
8072 Squamous cell carcinoma, large cell, nonkeratin			1	1.8%	1	1.8%
8140 Adenocarcinoma, NOS			18	32.1%	18	32.1%
8260 Papillary adenocarcinoma, NOS			1	1.8%	1	1.8%
8310 Clear cell adenocarcinoma, NOS			2	3.6%	2	3.6%
8460 Papillary serous cystadenocarcinoma			1	1.8%	1	1.8%
8800 Sarcoma, NOS			4	7.1%	4	7.1%
8890 Leiomyosarcoma, NOS			17	30.4%	17	30.4%
8935 Stromal sarcoma, NOS			1	1.8%	1	1.8%
8980 Carcinosarcoma, NOS			4	7.1%	4	7.1%
Total			**56**	**100.0%**	**56**	**100.0%**
C56 Ovary	**No**	**%**	**No**	**%**	**No**	**%**
8000 Neoplasm, malignant			106	15.6%	106	15.6%
8010 Carcinoma, NOS			9	1.3%	9	1.3%
8022 Pleomorphic carcinoma			1	0.1%	1	0.1%
8033 Pseudosarcomatous carcinoma			1	0.1%	1	0.1%
8041 Small cell carcinoma, NOS			2	0.3%	2	0.3%
8050 Papillary carcinoma, NOS			4	0.6%	4	0.6%
8052 Papillary squamous cell carcinoma			1	0.1%	1	0.1%
8070 Squamous cell carcinoma, NOS			6	0.9%	6	0.9%
8140 Adenocarcinoma, NOS			124	18.2%	124	18.2%
8211 Tubular adenocarcinoma			1	0.1%	1	0.1%

Site and histology	Male		Female		Total	
8260 Papillary adenocarcinoma, NOS			14	2.1%	14	2.1%
8310 Clear cell adenocarcinoma, NOS			21	3.1%	21	3.1%
8380 Endometrioid adenocarcinoma, NOS			42	6.2%	42	6.2%
8440 Cystadenocarcinoma, NOS			3	0.4%	3	0.4%
8441 Serous cystadenocarcinoma, NOS			91	13.4%	91	13.4%
8450 Papillary cystadenocarcinoma, NOS			7	1.0%	7	1.0%
8460 Papillary serous cystadenocarcinoma			138	20.3%	138	20.3%
8461 Serous surface papillary carcinoma			4	0.6%	4	0.6%
8470 Mucinous cystadenocarcinoma, NOS			25	3.7%	25	3.7%
8471 Papillary mucinous cystadenocarcinoma			9	1.3%	9	1.3%
8480 Mucinous adenocarcinoma			17	2.5%	17	2.5%
8481 Mucin-producing adenocarcinoma			1	0.1%	1	0.1%
8620 Granulosa cell tumour, malignant			15	2.2%	15	2.2%
8621 Granulosa cell-theca cell tumour			1	0.1%	1	0.1%
8631 Sertoli-Leydig cell tumour, poorly differentiated			1	0.1%	1	0.1%
8800 Sarcoma, NOS			1	0.1%	1	0.1%
8806 Desmoplastic small round cell tumour			1	0.1%	1	0.1%
8890 Leiomyosarcoma, NOS			1	0.1%	1	0.1%
8951 Mesodermal mixed tumour			1	0.1%	1	0.1%
8980 Carcinosarcoma, NOS			4	0.6%	4	0.6%
9000 Brenner tumor, malignant			1	0.1%	1	0.1%
9060 Dysgerminoma			6	0.9%	6	0.9%
9064 Germinoma			2	0.3%	2	0.3%
9071 Yolk sac tumour			5	0.7%	5	0.7%
9080 Teratoma, malignant, NOS			7	1.0%	7	1.0%
9084 Teratoma with malignant transformation			1	0.1%	1	0.1%
9085 Mixed germ cell tumour			5	0.7%	5	0.7%
9591 Malignant lymphoma, non-Hodgkin, NOS			1	0.1%	1	0.1%
Total			**680**	**100.0%**	**680**	**100.0%**
C57 Other and unspecified female genital organs	**No**	**%**	**No**	**%**	**No**	**%**
8070 Squamous cell carcinoma, NOS			2	28.6%	2	28.6%
8140 Adenocarcinoma, NOS			2	28.6%	2	28.6%
8380 Endometrioid adenocarcinoma, NOS			1	14.3%	1	14.3%
8890 Leiomyosarcoma, NOS			1	14.3%	1	14.3%
8980 Carcinosarcoma, NOS			1	14.3%	1	14.3%
Total			**7**	**100.0%**	**7**	**100.0%**
C58 Placenta	**No**	**%**	**No**	**%**	**No**	**%**
9100 Choriocarcinoma, NOS			18	90.0%	18	90.0%
9105 Trophoblastic tumour, epithelioid			2	10.0%	2	10.0%
Total			**20**	**100.0%**	**20**	**100.0%**
C60 Penis	**No**	**%**	**No**	**%**	**No**	**%**
8051 Verrucous carcinoma, NOS	3	3.9%			3	3.9%
8070 Squamous cell carcinoma, NOS	73	96.1%			73	96.1%
Total	**76**	**100.0%**			**76**	**100.0%**
C61 Prostate gland	**No**	**%**	**No**	**%**	**No**	**%**
8000 Neoplasm, malignant	71	14.8%			71	14.8%
8010 Carcinoma, NOS	6	1.3%			6	1.3%
8032 Spindle cell carcinoma, NOS	1	0.2%			1	0.2%
8070 Squamous cell carcinoma, NOS	4	0.8%			4	0.8%
8120 Transitional cell carcinoma, NOS	4	0.8%			4	0.8%
8140 Adenocarcinoma, NOS	303	63.1%			303	63.1%
8310 Clear cell adenocarcinoma, NOS	1	0.2%			1	0.2%

Site and histology	Male		Female		Total	
8480 Mucinous adenocarcinoma	2	0.4%			2	0.4%
8500 Infiltrating duct carcinoma, NOS	2	0.4%			2	0.4%
8550 Acinar cell carcinoma	86	17.9%			86	17.9%
Total	**480**	**100.0%**			**480**	**100.0%**
C62 Testis	**No**	**%**	**No**	**%**	**No**	**%**
8000 Neoplasm, malignant	1	2.2%			1	2.2%
8004 Malignant tumour, spindle cell type	1	2.2%			1	2.2%
8650 Leydig cell tumour, malignant	2	4.4%			2	4.4%
9061 Seminoma, NOS	18	40.0%			18	40.0%
9063 Spermatocytic seminoma	2	4.4%			2	4.4%
9064 Germinoma	3	6.7%			3	6.7%
9065 Germ cell tumor, nonseminomatous	3	6.7%			3	6.7%
9070 Embryonal carcinoma, NOS	3	6.7%			3	6.7%
9071 Yolk sac tumour	3	6.7%			3	6.7%
9080 Teratoma, malignant, NOS	3	6.7%			3	6.7%
9085 Mixed germ cell tumour	5	11.1%			5	11.1%
9591 Malignant lymphoma, non-Hodgkin, NOS	1	2.2%			1	2.2%
Total	**45**	**100.0%**			**45**	**100.0%**
C63 Other and unspecified male genital organs	**No**	**%**	**No**	**%**	**No**	**%**
8070 Squamous cell carcinoma, NOS	3	50.0%			3	50.0%
8850 Liposarcoma, NOS	2	33.3%			2	33.3%
8890 Leiomyosarcoma, NOS	1	16.7%			1	16.7%
Total	**6**	**100.0%**			**6**	**100.0%**
C64 Kidney	**No**	**%**	**No**	**%**	**No**	**%**
8000 Neoplasm, malignant	3	2.6%	0	0.0%	3	1.8%
8032 Spindle cell carcinoma, NOS	2	1.7%	0	0.0%	2	1.2%
8041 Small cell carcinoma, NOS	0	0.0%	1	1.9%	1	0.6%
8070 Squamous cell carcinoma, NOS	0	0.0%	1	1.9%	1	0.6%
8120 Transitional cell carcinoma, NOS	6	5.2%	1	1.9%	7	4.1%
C64 Kidney	**No**	**%**	**No**	**%**	**No**	**%**
8130 Papillary transitional cell carcinoma	1	0.9%	1	1.9%	2	1.2%
8140 Adenocarcinoma, NOS	2	1.7%	0	0.0%	2	1.2%
8260 Papillary adenocarcinoma, NOS	6	5.2%	3	5.7%	9	5.3%
8290 Oxyphilic adenocarcinoma	1	0.9%	0	0.0%	1	0.6%
8310 Clear cell adenocarcinoma, NOS	18	15.5%	8	15.1%	26	15.4%
8312 Renal cell carcinoma, NOS	60	51.7%	28	52.8%	88	52.1%
8317 Renal cell carcinoma, chromophobe type	0	0.0%	1	1.9%	1	0.6%
8806 Desmoplastic small round cell tumour	1	0.9%	0	0.0%	1	0.6%
8854 Pleomorphic liposarcoma	0	0.0%	1	1.9%	1	0.6%
8960 Nephroblastoma, NOS	15	12.9%	4	7.5%	19	11.2%
8964 Clear cell sarcoma of kidney	1	0.9%	4	7.5%	5	3.0%
Total	**116**	**100.0%**	**53**	**100.0%**	**169**	**100.0%**
C65 Renal pelvis	**No**	**%**	**No**	**%**	**No**	**%**
8070 Squamous cell carcinoma, NOS	0	0.0%	1	25.0%	1	12.5%
8120 Transitional cell carcinoma, NOS	2	50.0%	3	75.0%	5	62.5%
8130 Papillary transitional cell carcinoma	1	25.0%	0	0.0%	1	12.5%
8140 Adenocarcinoma, NOS	1	25.0%	0	0.0%	1	12.5%
Total	4	**100.0%**	**4**	**100.0%**	**8**	**100.0%**
C66 Ureter	**No**	**%**	**No**	**%**	**No**	**%**
8130 Papillary transitional cell carcinoma	1	100.0%			1	100.0%
Total	1	**100.0%**			**1**	**100.0%**

Site and histology	Male		Female		Total	
C67 Bladder	**No**	**%**	**No**	**%**	**No**	**%**
8000 Neoplasm, malignant	18	6.7%	1	1.5%	19	5.7%
8010 Carcinoma, NOS	2	0.7%	2	3.0%	4	1.2%
8050 Papillary carcinoma, NOS	1	0.4%	0	0.0%	1	0.3%
8070 Squamous cell carcinoma, NOS	11	4.1%	4	6.1%	15	4.5%
8120 Transitional cell carcinoma, NOS	184	68.4%	47	71.2%	231	69.0%
8130 Papillary transitional cell carcinoma	46	17.1%	8	12.1%	54	16.1%
8140 Adenocarcinoma, NOS	7	2.6%	2	3.0%	9	2.7%
8310 Clear cell adenocarcinoma, NOS	0	0.0%	1	1.5%	1	0.3%
8481 Mucin-producing adenocarcinoma	0	0.0%	1	1.5%	1	0.3%
Total	**269**	**100.0%**	**66**	**100.0%**	**335**	**100.0%**
C69 Eye and adnexa	**No**	**%**	**No**	**%**	**No**	**%**
8000 Neoplasm, malignant	0	0.0%	1	5.3%	1	2.0%
8070 Squamous cell carcinoma, NOS	4	12.5%	0	0.0%	4	7.8%
8200 Adenoid cystic carcinoma	1	3.1%	0	0.0%	1	2.0%
8720 Malignant melanoma, NOS	0	0.0%	1	5.3%	1	2.0%
9510 Retinoblastoma, NOS	26	81.3%	13	68.4%	39	76.5%
9591 Malignant lymphoma, non-Hodgkin, NOS	0	0.0%	2	10.5%	2	3.9%
9699 Marginal zone B-cell lymphoma, NOS	0	0.0%	2	10.5%	2	3.9%
9719 NK/T-cell lymphoma, nasal and nasal type	1	3.1%	0	0.0%	1	2.0%
Total	**32**	**100.0%**	**19**	**100.0%**	**51**	**100.0%**
C70 Meninges	**No**	**%**	**No**	**%**	**No**	**%**
9530 Meningioma, malignant	1	100.0%	1	100.0%	2	100.0%
Total	1	**100.0%**	**1**	**100.0%**	**2**	**100.0%**
C71 Brain	**No**	**%**	**No**	**%**	**No**	**%**
8000 Neoplasm, malignant	5	3.8%	3	2.8%	8	3.3%
8800 Sarcoma, NOS	0	0.0%	1	0.9%	1	0.4%
9064 Germinoma	0	0.0%	1	0.9%	1	0.4%
9150 Hemangiopericytoma, malignant	0	0.0%	2	1.9%	2	0.8%
9380 Glioma, malignant	18	13.6%	18	16.7%	36	15.0%
9381 Gliomatosis cerebri	1	0.8%	0	0.0%	1	0.4%
9382 Mixed glioma	2	1.5%	1	0.9%	3	1.3%
9390 Choroid plexus carcinoma	1	0.8%	0	0.0%	1	0.4%
9391 Ependymoma, NOS	4	3.0%	6	5.6%	10	4.2%
9392 Ependymoma, anaplastic	1	0.8%	1	0.9%	2	0.8%
9400 Astrocytoma, NOS	31	23.5%	21	19.4%	52	21.7%
9401 Astrocytoma, anaplastic	8	6.1%	5	4.6%	13	5.4%
9411 Gemistocytic astrocytoma	1	0.8%	0	0.0%	1	0.4%
9420 Fibrillary astrocytoma	1	0.8%	0	0.0%	1	0.4%
9440 Glioblastoma, NOS	43	32.6%	30	27.8%	73	30.4%
9441 Giant cell glioblastoma	0	0.0%	2	1.9%	2	0.8%
9450 Oligodendroglioma, NOS	8	6.1%	6	5.6%	14	5.8%
9451 Oligodendroglioma, anaplastic	1	0.8%	1	0.9%	2	0.8%
9470 Medulloblastoma, NOS	3	2.3%	7	6.5%	10	4.2%
9471 Desmoplastic nodular medulloblastoma	1	0.8%	0	0.0%	1	0.4%
9473 Primitive neuroectodermal tumour, NOS	1	0.8%	2	1.9%	3	1.3%
9474 Large cell medulloblastoma	1	0.8%	0	0.0%	1	0.4%
9590 Malignant lymphoma, NOS	1	0.8%	0	0.0%	1	0.4%
9680 Malignant lymphoma, large B-cell, diffuse, NOS	0	0.0%	1	0.9%	1	0.4%
Total	**132**	**100.0%**	**108**	**100.0%**	**240**	**100.0%**

Site and histology	Male		Female		Total	
C72 Spinal cord, cranial nerves and other parts of central nervous system	**No**	**%**	**No**	**%**	**No**	**%**
8000 Neoplasm, malignant	0	0.0%	1	12.5%	1	6.3%
8680 Paraganglioma, malignant	0	0.0%	1	12.5%	1	6.3%
8806 Desmoplastic small round cell tumour	0	0.0%	1	12.5%	1	6.3%
9150 Hemangiopericytoma, malignant	0	0.0%	1	12.5%	1	6.3%
9380 Glioma, malignant	0	0.0%	1	12.5%	1	6.3%
9391 Ependymoma, NOS	1	12.5%	1	12.5%	2	12.5%
9400 Astrocytoma, NOS	1	12.5%	0	0.0%	1	6.3%
9440 Glioblastoma, NOS	1	12.5%	0	0.0%	1	6.3%
9473 Primitive neuroectodermal tumour, NOS	1	12.5%	1	12.5%	2	12.5%
9490 Ganglioneuroblastoma	1	12.5%	1	12.5%	2	12.5%
9500 Neuroblastoma, NOS	1	12.5%	0	0.0%	1	6.3%
9540 Malignant peripheral nerve sheath tumour	1	12.5%	0	0.0%	1	6.3%
9930 Myeloid sarcoma	1	12.5%	0	0.0%	1	6.3%
Total	**8**	**100.0%**	**8**	**100.0%**	**16**	**100.0%**
C73 Thyroid gland	**No**	**%**	**No**	**%**	**No**	**%**
8000 Neoplasm, malignant	6	2.9%	21	2.5%	27	2.6%
8010 Carcinoma, NOS	1	0.5%	2	0.2%	3	0.3%
8013 Large cell neuroendocrine carcinoma	0	0.0%	1	0.1%	1	0.1%
8021 Carcinoma, anaplastic, NOS	9	4.4%	20	2.4%	29	2.8%
8050 Papillary carcinoma, NOS	3	1.5%	6	0.7%	9	0.9%
8070 Squamous cell carcinoma, NOS	1	0.5%	0	0.0%	1	0.1%
8072 Squamous cell carcinoma, large cell, nonkeratin	0	0.0%	1	0.1%	1	0.1%
8140 Adenocarcinoma, NOS	1	0.5%	4	0.5%	5	0.5%
8260 Papillary adenocarcinoma, NOS	134	65.7%	453	54.4%	587	56.7%
8290 Oxyphilic adenocarcinoma	5	2.5%	15	1.8%	20	1.9%
8330 Follicular adenocarcinoma, NOS	23	11.3%	152	18.3%	175	16.9%
8335 Follicular carcinoma, minimally invasive	0	0.0%	13	1.6%	13	1.3%
8340 Papillary carcinoma, follicular variant	10	4.9%	86	10.3%	96	9.3%
8341 Papillary microcarcinoma	4	2.0%	40	4.8%	44	4.2%
8343 Papillary carcinoma, encapsulated	0	0.0%	1	0.1%	1	0.1%
8510 Medullary carcinoma, NOS	6	2.9%	11	1.3%	17	1.6%
9120 Hemangiosarcoma	0	0.0%	1	0.1%	1	0.1%
9591 Malignant lymphoma, non-Hodgkin, NOS	0	0.0%	1	0.1%	1	0.1%
9680 Malignant lymphoma, large B-cell, diffuse, NOS	0	0.0%	3	0.4%	3	0.3%
9699 Marginal zone B-cell lymphoma, NOS	1	0.5%	1	0.1%	2	0.2%
Total	**204**	**100.0%**	**832**	**100.0%**	**1036**	**100.0%**
C74 Adrenal gland	**No**	**%**	**No**	**%**	**No**	**%**
8000 Neoplasm, malignant	4	20.0%	1	3.8%	5	10.9%
8010 Carcinoma, NOS	1	5.0%	2	7.7%	3	6.5%
8140 Adenocarcinoma, NOS	0	0.0%	3	11.5%	3	6.5%
8370 Adrenal cortical carcinoma	2	10.0%	2	7.7%	4	8.7%
8700 Pheochromocytoma, malignant	3	15.0%	1	3.8%	4	8.7%
8890 Leiomyosarcoma, NOS	0	0.0%	2	7.7%	2	4.3%
9490 Ganglioneuroblastoma	1	5.0%	0	0.0%	1	2.2%
9500 Neuroblastoma, NOS	9	45.0%	15	57.7%	24	52.2%
Total	**20**	**100.0%**	**26**	**100.0%**	**46**	**100.0%**
C75 Other endocrine glands and related structures	**No**	**%**	**No**	**%**	**No**	**%**
8140 Adenocarcinoma, NOS	1	50.0%			1	50.0%
9362 Pineoblastoma	1	50.0%			1	50.0%
Total	**2**	**100.0%**			**2**	**100.0%**

Site and histology	Male		Female		Total	
C76 Other and ill-defined sites	**No**	**%**	**No**	**%**	**No**	**%**
8000 Neoplasm, malignant	2	22.2%	5	33.3%	7	29.2%
8010 Carcinoma, NOS	1	11.1%	2	13.3%	3	12.5%
8140 Adenocarcinoma, NOS	0	0.0%	3	20.0%	3	12.5%
8246 Neuroendocrine carcinoma, NOS	1	11.1%	0	0.0%	1	4.2%
9071 Yolk sac tumour	1	11.1%	1	6.7%	2	8.3%
9080 Teratoma, malignant, NOS	1	0.0%	3	20.0%	4	16.7%
9500 Neuroblastoma, NOS	3	33.3%	1	6.7%	4	16.7%
Total	**9**	**100.0%**	**15**	**100.0%**	**24**	**100.0%**
C77 Lymph nodes	**No**	**%**	**No**	**%**	**No**	**%**
9590 Malignant lymphoma, NOS	26	7.2%	16	7.2%	42	7.2%
9591 Malignant lymphoma, non-Hodgkin, NOS	152	42.1%	101	45.3%	253	43.3%
9650 Hodgkin lymphoma, NOS	23	6.4%	16	7.2%	39	6.7%
9651 Hodgkin lymphoma, lymphocyte-rich	5	1.4%	3	1.3%	8	1.4%
9652 Hodgkin lymphoma, mixed cellularity, NOS	18	5.0%	8	3.6%	26	4.5%
9653 Hodgkin lymphoma, lymphocyte depletion, NOS	0	0.0%	2	0.9%	2	0.3%
9659 Hodgkin lymphoma, nodular lymphocyte predominance	1	0.3%	0	0.0%	1	0.2%
9663 Hodgkin lymphoma, nodular sclerosis, NOS	19	5.3%	12	5.4%	31	5.3%
9664 Hodgkin lymphoma, nodular sclerosis, cellular phase	0	0.0%	1	0.4%	1	0.2%
9665 Hodgkin lymphoma, nodular sclerosis, grade 1	0	0.0%	1	0.4%	1	0.2%
9670 Malignant lymphoma, small B lymphocytic, NOS	6	1.7%	5	2.2%	11	1.9%
9671 Malignant lymphoma, lymphoplasmacytic	1	0.3%	2	0.9%	3	0.5%
9673 Mantle cell lymphoma	7	1.9%	3	1.3%	10	1.7%
9675 Malignant lymphoma, mixed small and large cell, diffuse	0	0.0%	1	0.4%	1	0.2%
9680 Malignant lymphoma, large B-cell, diffuse, NOS	40	11.1%	22	9.9%	62	10.6%
9684 malignant lymphoma, large B-cell, diffuse, immunoblastic, NOS	1	0.3%	0	0.0%	1	0.2%
9687 Burkitt lymphoma, NOS	3	0.8%	3	1.3%	6	1.0%
9690 Follicular lymphoma, NOS	33	9.1%	15	6.7%	48	8.2%
9691 Follicular lymphoma, grade 2	1	0.3%	0	0.0%	1	0.2%
9695 Follicular lymphoma, grade 1	1	0.3%	0	0.0%	1	0.2%
9699 Marginal zone B-cell lymphoma, NOS	3	0.8%	1	0.4%	4	0.7%
9702 Mature T-cell lymphoma, NOS	6	1.7%	5	2.2%	11	1.9%
9714 Anaplastic large cell lymphoma, T cell and Null cell type	7	1.9%	2	0.9%	9	1.5%
9727 Precursor cell lymphoblastic lymphoma, NOS	5	1.4%	3	1.3%	8	1.4%
9728 Precursor B-cell lymphoblastic lymphoma	1	0.3%	0	0.0%	1	0.2%
9729 Precursor T-cell lymphoblasic lymphoma	2	0.6%	1	0.4%	3	0.5%
Total	**361**	**100.0%**	**223**	**100.0%**	**584**	**100.0%**
C80 Unknown primary site	**No**	**%**	**No**	**%**	**No**	**%**
8000 Neoplasm, malignant	160	36.7%	108	39.7%	268	37.9%
8010 Carcinoma, NOS	23	5.3%	14	5.1%	37	5.2%
8021 Carcinoma, anaplastic, NOS	2	0.5%	0	0.0%	2	0.3%
8041 Small cell carcinoma, NOS	3	0.7%	0	0.0%	3	0.4%
8050 Papillary carcinoma, NOS	7	1.6%	2	0.7%	9	1.3%
8070 Squamous cell carcinoma, NOS	114	26.1%	36	13.2%	150	21.2%
8071 Squamous cell carcinoma, keratinizing, NOS	1	0.2%	1	0.4%	2	0.3%
8072 Squamous cell carcinoma, large cell, nonkeratin	0	0.0%	1	0.4%	1	0.1%
8140 Adenocarcinoma, NOS	98	22.5%	91	33.5%	189	26.7%
8200 Adenoid cystic carcinoma	2	0.5%	0	0.0%	2	0.3%
8211 Tubular adenocarcinoma	1	0.2%	0	0.0%	1	0.1%
8240 Carcinoid tumor, NOS	1	0.2%	0	0.0%	1	0.1%
8246 Neuroendocrine carcinoma, NOS	1	0.2%	2	0.7%	3	0.4%

Site and histology		Male		Female		Total	
C80	**Unknown primary site**	**No**	**%**	**No**	**%**	**No**	**%**
8260	Papillary adenocarcinoma, NOS	5	1.1%	2	0.7%	7	1.0%
8310	Clear cell adenocarcinoma, NOS	0	0.0%	1	0.4%	1	0.1%
8430	Mucoepidermoid carcinoma	2	0.5%	1	0.4%	3	0.4%
8480	Mucinous adenocarcinoma	6	1.4%	3	1.1%	9	1.3%
8481	Mucin-producing adenocarcinoma	2	0.5%	3	1.1%	5	0.7%
8490	Signet ring cell carcinoma	2	0.5%	1	0.4%	3	0.4%
8560	Adenosquamous carcinoma	2	0.5%	0	0.0%	2	0.3%
8980	Carcinosarcoma, NOS	0	0.0%	1	0.4%	1	0.1%
9064	Germinoma	1	0.2%	2	0.7%	3	0.4%
9071	Yolk sac tumour	0	0.0%	1	0.4%	1	0.1%
9500	Neuroblastoma, NOS	3	0.7%	1	0.4%	4	0.6%
9734	Plasmacytoma, extramedullary	0	0.0%	1	0.4%	1	0.1%
Total		**436**	**100.0%**	**272**	**100.0%**	**708**	**100.0%**

Table 15: Lip, oral cavity and pharynx- Incidence data 2010

Group	Number	Percentage	ASR	Cum. Rate
Male	1888	23.6	20.7	2.56
Female	534	6.0	5.4	0.66
Total	2422	14.3	12.7	1.56

ASR: Age standardized rate per 100,000 world population

Cum. Rate- Cumulative Rate (0-74 years) per 100 population

ICD O code and site	Male	Female	Total
C00.0 External upper lip	3	4	7
C00.1 External lower lip	15	9	24
C00.2 External lip, NOS	2	0	2
C00.4 Mucosa of lower lip	0	1	1
C00.6 Commissure of lip	27	5	32
C00.8 Overlapping lesion of lip	2	0	2
C00.9 Lip, NOS	15	7	22
C01.9 Base of tongue, NOS	117	13	130
C02.0 Dorsal surface of tongue, NOS	1	0	1
C02.1 Border of tongue	22	2	24
C02.2 Ventral surface of tongue, NOS	3	1	4
C02.3 Anterior 2/3 of tongue, NOS	52	7	59
C02.8 Overlapping lesion of tongue	5	2	7
C02.9 Tongue, NOS	290	58	348
C03.0 Upper gum	22	9	31
C03.1 Lower gum	46	22	68
C03.9 Gum, NOS	47	20	67
C04.1 Lateral floor of mouth	2	0	2
C04.9 Floor of mouth, NOS	99	16	115
C05.0 Hard palate	7	14	21
C05.1 Soft palate, NOS	59	6	65
C05.2 Uvula	2	2	4
C05.8 Overlapping lesion of palate	5	2	7
C05.9 Palate, NOS	31	13	44
C06.0 Cheek mucosa	299	127	426
C06.1 Vestibule of mouth	11	1	12
C06.2 Retromolar area	43	10	53
C06.8 Overlapping lesion of other/unspec. parts of mouth	11	5	16
C06.9 Mouth, NOS	151	69	220
C09.0 Tonsillar fossa	7	0	7
C09.1 Tonsillar pillar	2	0	2
C09.8 Overlapping lesion of tonsil	2	0	2
C09.9 Tonsil, NOS	120	23	143
C10.0 Vallecula	55	5	60
C10.3 Posterior wall of oropharynx	1	0	1
C10.8 Overlapping lesion of oropharynx	2	0	2
C10.9 Oropharynx, NOS	28	1	29
C11.1 Posterior wall of nasopharynx	2	0	2
C11.9 Nasopharynx, NOS	26	12	38
C12.9 Pyriform sinus	169	18	187
C13.0 Postcricoid region	15	21	36
C13.1 Aryepiglottic fold	7	0	7
C13.2 Posterior wall of hypopharynx	1	0	1

ICD O code and site	Male	Female	Total
C13.9 Hypopharynx NOS	3	1	4
C14.0 Pharynx, NOS	54	25	79
C14.8 Overlapping lesion of lip, oral cavity, pharynx	5	3	8
Total	**1888**	**534**	**2422**

ICD O code and histology	Male	Female	Total
800 Neoplasms, NOS	55	25	80
801-804 Epithelial neoplasms, NOS	35	15	50
805-808 Squamous cell neoplasms	1750	452	2202
814-838 Adenocarcinomas	16	20	36
843 Mucoepidermoid neoplasms	11	12	23
844-849 Cystic, mucinous and serous neoplasms	1	0	1
855 Acinar cell neoplasms	2	0	2
872-879 Malignant nevi and melanomas	1	2	3
889-892 Myomatous neoplasms	1	1	2
893-899 Complex mixed and stromal neoplasms	1	1	2
959 Malignant lymphomas, NOS or diffuse	5	2	7
965-966 Hodgkin lymphoma	2	0	2
967-969 Mature B-cell lymphomas	8	4	12
Total	1888	534	2422



Figure 14: Age specific rates- Lip, oral cavity and pharynx



Figure 15: ASR, 1985-2010, Lip, oral cavity and pharynx

Table 16: Lip and anterior part of oral cavity -Incidence data 2010

Group	Number	Percentage	ASR	Cum. Rate
Male	1175	14.7	12.8	1.55
Female	389	4.3	3.9	0.48
Total	1564	9.2	8.2	0.99

ASR: Age standardized rate per 100,000 world population

Cum. Rate- Cumulative Rate (0-74 years) per 100 population

ICD O code and site	Male	Female	Total
C00.0 External upper lip	3	4	7
C00.1 External lower lip	15	9	24
C00.2 External lip, NOS	2	0	2
C00.4 Mucosa of lower lip	0	1	1
C00.6 Commissure of lip	27	5	32
C00.8 Overlapping lesion of lip	2	0	2
C00.9 Lip, NOS	15	7	22
C02.0 Dorsal surface of tongue, NOS	1	0	1
C02.1 Border of tongue	22	2	24
C02.2 Ventral surface of tongue, NOS	3	1	4
C02.3 Anterior 2/3 of tongue, NOS	52	7	59
C02.8 Overlapping lesion of tongue	5	2	7
C02.9 Tongue, NOS	290	58	348
C03.0 Upper gum	22	9	31
C03.1 Lower gum	46	22	68
C03.9 Gum, NOS	47	20	67
C04.1 Lateral floor of mouth	2	0	2
C04.9 Floor of mouth, NOS	99	16	115
C05.0 Hard palate	7	14	21
C06.0 Cheek mucosa	299	127	426
C06.1 Vestibule of mouth	11	1	12
C06.2 Retromolar area	43	10	53
C06.8 Overlapping lesion of other/unspecified parts of mouth	11	5	16
C06.9 Mouth, NOS	151	69	220
Total	1175	389	1564

ICD O code and histology	Male	Female	Total
800 Neoplasms, NOS	32	15	47
801-804 Epithelial neoplasms, NOS	12	9	21
805-808 Squamous cell neoplasms	1108	337	1445
814-838 Adenocarcinomas	11	15	26
843 Mucoepidermoid neoplasms	7	9	16
855 Acinar cell neoplasms	2	0	2
872-879 Malignant nevi and melanomas	0	2	2
889-892 Myomatous neoplasms	1	0	1
893-899 Complex mixed and stromal neoplasms	1	1	2
959 Malignant lymphomas, NOS or diffuse	0	1	1
967-969 Mature B-cell lymphomas	1	0	1
Total	1175	389	1564

Table 17: Posterior part of oral cavity and pharynx -Incidence data 2010

Group	Number	Percentage	ASR	Cum. Rate
Male	713	8.9	7.8	1.01
Female	145	1.6	1.4	0.18
Total	858	5.1	4.5	0.57

ASR: Age standardized rate per 100,000 world population

Cum. Rate- Cumulative Rate (0-74 years) per 100 population

ICD O code and site	Male	Female	Total
C01.9 Base of tongue, NOS	117	13	130
C05.1 Soft palate, NOS	59	6	65
C05.2 Uvula	2	2	4
C05.8 Overlapping lesion of palate	5	2	7
C05.9 Palate, NOS	31	13	44
C09.0 Tonsillar fossa	7	0	7
C09.1 Tonsillar pillar	2	0	2
C09.8 Overlapping lesion of tonsil	2	0	2
C09.9 Tonsil, NOS	120	23	143
C10.0 Vallecula	55	5	60
C10.3 Posterior wall of oropharynx	1	0	1
C10.8 Overlapping lesion of oropharynx	2	0	2
C10.9 Oropharynx, NOS	28	1	29
C11.1 Posterior wall of nasopharynx	2	0	2
C11.9 Nasopharynx, NOS	26	12	38
C12.9 Pyriform sinus	169	18	187
C13.0 Postcricoid region	15	21	36
C13.1 Aryepiglottic fold	7	0	7
C13.2 Posterior wall of hypopharynx	1	0	1
C13.9 Hypopharynx NOS	3	1	4
C14.0 Pharynx, NOS	54	25	79
C14.8 Overlapping lesion of lip, oral cavity, pharynx	5	3	8
Total	713	145	858

ICD O code and histology	Male	Female	Total
800 Neoplasms, NOS	23	10	33
801-804 Epithelial neoplasms, NOS	23	6	29
805-808 Squamous cell neoplasms	642	115	757
814-838 Adenocarcinomas	5	5	10
843 Mucoepidermoid neoplasms	4	3	7
844-849 Cystic, mucinous and serous neoplasms	1	0	1
872-879 Malignant nevi and melanomas	1	0	1
889-892 Myomatous neoplasms	0	1	1
959 Malignant lymphomas, NOS or diffuse	5	1	6
965-966 Hodgkin lymphoma	2	0	2
967-969 Mature B-cell lymphomas	7	4	11
Total	713	145	858

Table 18: Oesophagus- Incidence data 2010

Group	Number	Percentage	ASR	Cum. Rate
Male	574	7.2	6.5	0.82
Female	496	5.5	5.1	0.62
Total	1070	6.3	5.7	0.72

ASR: Age standardized rate per 100,000 world population

Cum. Rate- Cumulative Rate (0-74 years) per 100 population

ICD O code and site	Male	Female	Total
C15.0 Cervical oesophagus	0	1	1
C15.2 Abdominal oesophagus	2	0	2
C15.3 Upper third of oesophagus	15	15	30
C15.4 Middle third of oesophagus	109	127	236
C15.5 Lower third of oesophagus	187	140	327
C15.8 Overlapping lesion of oesophagus	4	1	5
C15.9 Oesophagus, NOS	257	212	469
Total	574	496	1070

ICD O code and histology	Male	Female	Total
800 Neoplasms, NOS	41	29	70
801-804 Epithelial neoplasms, NOS	12	10	22
805-808 Squamous cell neoplasms	430	423	853
814-838 Adenocarcinomas	87	31	118
843 Mucoepidermoid neoplasms	0	1	1
844-849 Cystic, mucinous and serous neoplasms	4	1	5
856-857 Complex epithelial neoplasms	0	1	1
Total	574	496	1070



Figure 16: Age specific rates- Oesophagus



Figure 17: ASR, 1985-2010, Oesophagus

Table 19: Stomach- Incidence data 2010

Group	Number	Percentage	ASR	Cum. Rate
Male	226	2.8	2.5	0.31
Female	97	1.1	1.0	0.12
Total	323	1.9	1.7	0.21

ASR: Age standardized rate per 100,000 world population

Cum. Rate- Cumulative Rate (0-74 years) per 100 population

ICD O code and site	Male	Female	Total
C16.0 Cardia, NOS	52	34	86
C16.1 Fundus of stomach	4	0	4
C16.2 Body of stomach	2	0	2
C16.3 Gastric antrum	4	1	5
C16.4 Pylorus	10	5	15
C16.6 Greater curvature of stomach, NOS	1	0	1
C16.8 Overlapping lesion of stomach	2	0	2
C16.9 Stomach, NOS	151	57	208
Total	226	97	323

ICD O code and histology	Male	Female	Total
800 Neoplasms, NOS	23	9	32
801-804 Epithelial neoplasms, NOS	10	4	14
805-808 Squamous cell neoplasms	14	12	26
814-838 Adenocarcinomas	150	55	205
844-849 Cystic, mucinous and serous neoplasms	23	9	32
893-899 Complex mixed and stromal neoplasms	5	7	12
959 Malignant lymphomas, NOS or diffuse	1	0	1
967-969 Mature B-cell lymphomas	0	1	1
Total	226	97	323



Figure 18: Age specific rates- Stomach



Figure 19: ASR, 1985-2010, Stomach

Table 20: Colon - Incidence data 2010

Group	Number	Percentage	ASR	Cum. Rate
Male	221	2.8	2.3	0.29
Female	222	2.5	2.2	0.25
Total	443	2.6	2.3	0.27

ASR: Age standardized rate per 100,000 world population

Cum. Rate- Cumulative Rate (0-74 years) per 100 population

ICD O code and site	Male	Female	Total
C18.0 Cecum	32	19	51
C18.1 Appendix	7	3	10
C18.2 Ascending colon	16	12	28
C18.3 Hepatic flexure of colon	2	5	7
C18.4 Transverse colon	9	15	24
C18.5 Splenic flexure of colon	2	3	5
C18.6 Descending colon	7	8	15
C18.7 Sigmoid colon	79	98	177
C18.8 Overlapping lesion of colon	6	5	11
C18.9 Colon, NOS	61	54	115
Total	221	222	443

ICD O code and histology	Male	Female	Total
800 Neoplasms, NOS	8	12	20
801-804 Epithelial neoplasms, NOS	2	3	5
805-808 Squamous cell neoplasms	3	0	3
814-838 Adenocarcinomas	185	193	378
844-849 Cystic, mucinous and serous neoplasms	19	13	32
893-899 Complex mixed and stromal neoplasms	1	0	1
959 Malignant lymphomas, NOS or diffuse	1	1	2
967-969 Mature B-cell lymphomas	2	0	2
Total	221	222	443



Figure 20: Age specific rates- Colon



Figure 21: ASR 1985-2010, Colon

Table 21: Colon and rectum- Incidence data 2010

Group	Number	Percentage	ASR	Cum. Rate
Male	567	7.1	6.2	0.80
Female	516	5.8	5.1	0.63
Total	1083	6.4	5.6	0.72

ASR: Age standardized rate per 100,000 world population

Cum. Rate- Cumulative Rate (0-74 years) per 100 population

ICD O code and site	Male	Female	Total
C18.0 Cecum	32	19	51
C18.1 Appendix	7	3	10
C18.2 Ascending colon	16	12	28
C18.3 Hepatic flexure of colon	2	5	7
C18.4 Transverse colon	9	15	24
C18.5 Splenic flexure of colon	2	3	5
C18.6 Descending colon	7	8	15
C18.7 Sigmoid colon	79	98	177
C18.8 Overlapping lesion of colon	6	5	11
C18.9 Colon, NOS	61	54	115
C19.9 Rectosigmoid junction	30	46	76
C20.9 Rectum, NOS	316	248	564
Total	567	516	1083

ICD O code and histology	Male	Female	Total
800 Neoplasms, NOS	24	27	51
801-804 Epithelial neoplasms, NOS	3	5	8
805-808 Squamous cell neoplasms	12	4	16
814-838 Adenocarcinomas	484	453	937
844-849 Cystic, mucinous and serous neoplasms	34	24	58
856-857 Complex epithelial neoplasms	0	1	1
872-879 Malignant nevi and melanomas	3	0	3
880 Soft tissue tumours and sarcomas, NOS	1	0	1
893-899 Complex mixed and stromal neoplasms	3	0	3
959 Malignant lymphomas, NOS or diffuse	1	1	2
967-969 Mature B-cell lymphomas	2	1	3
Total	567	516	1083



Figure 22: Age specific rates- Colon and rectum



Figure 23: ASR, 1985-2010- Colon and rectum

Table 22: Rectum, anal canal and anus- Incidence data 2010

Group	Number	Percentage	ASR	Cum. Rate
Male	344	4.3	3.8	0.47
Female	270	3.0	2.7	0.34
Total	614	3.6	3.2	0.40

ASR: Age standardized rate per 100,000 world population

Cum. Rate- Cumulative Rate (0-74 years) per 100 population

ICD O code and site	Male	Female	Total
C20.9 Rectum, NOS	316	248	564
C21.0 Anus, NOS	25	14	39
C21.1 Anal canal	2	6	8
C21.8 Overlapping lesion rectum, anal canal	1	2	3
Total	344	270	614

ICD O code and histology	Male	Female	Total
800 Neoplasms, NOS	15	13	28
801-804 Epithelial neoplasms, NOS	2	1	3
805-808 Squamous cell neoplasms	26	11	37
812-813 Transitional cell carcinomas	2	1	3
814-838 Adenocarcinomas	278	232	510
844-849 Cystic, mucinous and serous neoplasms	14	9	23
856-857 Complex epithelial neoplasms	0	1	1
872-879 Malignant nevi and melanomas	3	1	4
880 Soft tissue tumours and sarcomas, NOS	2	0	2
893-899 Complex mixed and stromal neoplasms	2	0	2
967-969 Mature B-cell lymphomas	0	1	1
Total	344	270	614



Figure 24: Age specific rates- Rectum, anal canal and anus



Figure 25: ASR, 1985-2010, Rectum, anal canal and anus

Table 23: Larynx- Incidence data 2010

Group	Number	Percentage	ASR	Cum. Rate
Male	384	4.8	4.3	0.54
Female	36	0.4	0.4	0.05
Total	420	2.5	2.2	0.29

ASR: Age standardized rate per 100,000 world population

Cum. Rate- Cumulative Rate (0-74 years) per 100 population

ICD O code and site	Male	Female	Total
C32.0 Glottis	186	13	199
C32.1 Supraglottis	144	15	159
C32.2 Subglottis	7	2	9
C32.3 Laryngeal cartilage	9	0	9
C32.8 Overlapping lesion of larynx	4	1	5
C32.9 Larynx, NOS	34	5	39
Total	384	36	420

ICD O code and histology	Male	Female	Total
800 Neoplasms, NOS	9	3	12
801-804 Epithelial neoplasms, NOS	6	2	8
805-808 Squamous cell neoplasms	367	29	396
814-838 Adenocarcinomas	2	2	4
Total	384	36	420



Figure 26: Age specific rates- Larynx



Figure 27: ASR, 1985-2010, Larynx

Table 24: Trachea, bronchus and lungs- Incidence data 2010

Group	Number	Percentage	ASR	Cum. Rate
Male	806	10.1	9.0	1.19
Female	209	2.3	2.1	0.25
Total	1015	6.0	5.4	0.70

ASR: Age standardized rate per 100,000 world population

Cum. Rate- Cumulative Rate (0-74 years) per 100 population

ICD O code and site	Male	Female	Total
C33.9 Trachea	5	0	5
C34.0 Main bronchus	4	1	5
C34.1 Upper lobe, lung	21	4	25
C34.2 Middle lobe, lung	3	0	3
C34.3 Lower lobe, lung	14	1	15
C34.8 Overlapping lesion of lung	0	2	2
C34.9 Lung, NOS	759	201	960
Total	806	209	1015

ICD O code and histology	Male	Female	Total
800 Neoplasms, NOS	159	34	193
801-804 Epithelial neoplasms, NOS	211	40	251
805-808 Squamous cell neoplasms	260	39	301
814-838 Adenocarcinomas	169	92	261
844-849 Cystic, mucinous and serous neoplasms	2	2	4
880 Soft tissue tumours and sarcomas, NOS	0	1	1
881-883 Fibromatous neoplasms	0	1	1
889-892 Myomatous neoplasms	2	0	2
959 Malignant lymphomas, NOS or diffuse	1	0	1
965-966 Hodgkin lymphoma	1	0	1
975 Neoplasms of histiocytes and accessory lymphoid cells	1	0	1
Total	806	209	1015



Figure 28: Age specific rates- Trachea, bronchus and lungs



Figure 29: ASR, 1985-2010, Trachea, bronchus and lungs

Table 25: Hematopoietic and reticuloendothelial system - Incidence data 2010

Group	Number	Percentage	ASR	Cum. Rate
Male	555	6.9	6.0	0.59
Female	499	5.6	5.0	0.54
Total	1054	6.2	5.5	0.56

ASR: Age standardized rate per 100,000 world population

Cum. Rate- Cumulative Rate (0-74 years) per 100 population

ICD O code and site	Male	Female	Total
C42.1 Bone marrow	554	496	1050
C42.2 Spleen	1	3	4
Total	555	499	1054

ICD O code and histology	Male	Female	Total
912-916 Blood vessel tumours	0	1	1
959 Malignant lymphomas, NOS or diffuse	13	13	26
965-966 Hodgkin lymphoma	1	1	2
967-969 Mature B-cell lymphomas	3	2	5
972 Precursor cell lymphoblastic lymphoma	1	0	1
973 Plasma cell tumours	123	121	244
975 Neoplasms of histiocytes and accessory lymphoid cells	1	0	1
980 Leukemias, NOS	3	2	5
982-983 Lymphoid leukemias	168	116	284
984-993 Myeloid leukemias	190	174	364
994 Other leukemias	4	2	6
995-996 Chronic myeloproliferative disorders	14	8	22
998 Myelodysplastic syndromes	34	59	93
Total	555	496	1054



Figure 30: Age specific rates- Hematopoietic and reticuloendothelial system



Figure 31: ASR, 1985-2010, Hematopoietic and reticuloendothelial system

Table 26: Skin - Incidence data 2010

Group	Number	Percentage	ASR	Cum. Rate
Male	158	2.0	1.7	0.19
Female	141	1.6	1.4	0.17
Total	299	1.8	1.5	0.18

ASR: Age standardized rate per 100,000 world population

Cum. Rate- Cumulative Rate (0-74 years) per 100 population

ICD O code and site	Male	Female	Total
C44.0 Skin of lip, NOS	1	2	3
C44.1 Eyelid	3	6	9
C44.2 External ear	6	5	11
C44.3 Skin, other & unspecified parts of face	18	23	41
C44.4 Skin of scalp and neck	4	8	12
C44.5 Skin of trunk	22	14	36
C44.6 Skin of upper limb and shoulder	8	11	19
C44.7 Skin of lower limb and hip	54	32	86
C44.9 Skin, NOS	42	40	82
Total	158	141	299

ICD O code and histology	Male	Female	Total
800 Neoplasms, NOS	3	3	6
801-804 Epithelial neoplasms, NOS	2	2	4
805-808 Squamous cell neoplasms	82	52	134
809-811 Basal cell neoplasms	15	33	48
814-838 Adenocarcinomas	1	1	2
839-842 Adnexal and skin appendage neoplasms	7	5	12
843 Mucoepidermoid neoplasms	0	2	2
872-879 Malignant nevi and melanomas	38	27	65
881-883 Fibromatous neoplasms	6	3	9
893-899 Complex mixed and stromal neoplasms	0	1	1
912-916 Blood vessel tumours	0	2	2
959 Malignant lymphomas, NOS or diffuse	1	3	4
970-971 Mature T-cell and NK-cell lymphomas	3	7	10
Total	158	141	299



Figure 32: Age specific rates- Skin



Figure 33: ASR, 1985-2010, Skin

Table 27: Breast- Incidence data 2010

Group	Number	Percentage	ASR	Cum. Rate
Male	39	0.5	0.4	0.05
Female	2401	26.8	23.0	2.56
Total	2440	14.4	12.1	1.35

ASR: Age standardized rate per 100,000 world population

Cum. Rate- Cumulative Rate (0-74 years) per 100 population

ICD O code and site	Male	Female	Total
C50.0 Nipple	0	2	2
C50.4 Upper-outer quadrant of breast	0	2	2
C50.6 Axillary tail of breast	0	1	1
C50.9 Breast, NOS	39	2396	2435
Total	39	2401	2440

CD O code and histology	Male	Female	Total
800 Neoplasms, NOS	2	118	120
801-804 Epithelial neoplasms, NOS	2	32	34
805-808 Squamous cell neoplasms	0	7	7
814-838 Adenocarcinomas	1	21	22
844-849 Cystic, mucinous and serous neoplasms	0	21	21
850-854 Ductal and lobular neoplasms	34	2179	2213
856-857 Complex epithelial neoplasms	0	8	8
880 Soft tissue tumours and sarcomas, NOS	0	1	1
889-892 Myomatous neoplasms	0	2	2
893-899 Complex mixed and stromal neoplasms	0	3	3
900-903 Fibroepithelial neoplasms	0	5	5
912-916 Blood vessel tumours	0	3	3
970-971 Mature T-cell and NK-cell lymphomas	0	1	1
Total	39	2401	2440



Figure 34: Age specific rates- Breast



Figure 35: ASR, 1985-2010, Breast

Table 28: Cervix uteri- Incidence data 2010

Group	Number	Percentage	ASR	Cum. Rate
Female	847	9.7	8.4	1.02

ASR: Age standardized rate per 100,000 world population

Cum. Rate- Cumulative Rate (0-74 years) per 100 population

ICD O code and site	Female
C53.0 Endocervix	6
C53.9 Cervix uteri	841
Total	847

ICD O code and histology	Female
800 Neoplasms, NOS	45
801-804 Epithelial neoplasms, NOS	18
805-808 Squamous cell neoplasms	754
809-811 Basal cell neoplasms	1
814-838 Adenocarcinomas	25
844-849 Cystic, mucinous and serous neoplasms	2
856-857 Complex epithelial neoplasms	2
Total	847



Figure 36: Age specific rates- Cervix uteri



Figure 37: ASR, 1985-2010, Cervix uteri

Table 29: Ovary - Incidence data 2010

Group	Number	Percentage	ASR	Cum. Rate
Female	680	7.6	6.7	0.76

ASR: Age standardized rate per 100,000 world population

Cum. Rate- Cumulative Rate (0-74 years) per 100 population

ICD O code and site		Female
C56.9	Ovary	680
	Total	680

ICD O code and histology		Female
800	Neoplasms, NOS	106
801-804	Epithelial neoplasms, NOS	13
805-808	Squamous cell neoplasms	11
814-838	Adenocarcinomas	202
844-849	Cystic, mucinous and serous neoplasms	295
859-867	Specialised gonadal neoplasms	17
880	Soft tissue tumours and sarcomas, NOS	2
889-892	Myomatous neoplasms	1
893-899	Complex mixed and stromal neoplasms	5
900-903	Fibroepithelial neoplasms	1
906-909	Germ cell neoplasms	26
959	Malignant lymphomas, NOS or diffuse	1
	Total	680



Figure 38: Age specific rates- Ovary



Figure 39: ASR, 1985-2010, Ovary

Table 30: Prostate gland - Incidence data 2010

Group	Number	Percentage	ASR	Cum. Rate
Male	480	6.0	4.4	0.34

ASR: Age standardized rate per 100,000 world population

Cum. Rate- Cumulative Rate (0-74 years) per 100 population

ICD O code and site		Male
C61.9	Prostate gland	480
	Total	480

ICD O code and histology		Male
800	Neoplasms, NOS	71
801-804	Epithelial neoplasms, NOS	7
805-808	Squamous cell neoplasms	4
812-813	Transitional cell carcinomas	4
814-838	Adenocarcinomas	304
844-849	Cystic, mucinous and serous neoplasms	2
850-854	Ductal and lobular neoplasms	2
855	Acinar cell neoplasms	86
	Total	480



Figure 40: Age specific rates- Prostate gland



Figure 41: ASR, 1985-2010, Prostate gland

Table 31: Urinary bladder - Incidence data 2010

Group	Number	Percentage	ASR	Cum. Rate
Male	269	3.4	3.0	0.37
Female	66	0.7	0.7	0.07
Total	335	2.0	1.8	0.21

ASR: Age standardized rate per 100,000 world population

Cum. Rate- Cumulative Rate (0-74 years) per 100 population

ICD O code and site	Male	Female	Total
C67.6 Ureteric orifice	1	0	1
C67.9 Urinary bladder, NOS	268	66	334
Total	269	66	335

ICD O code and histology	Male	Female	Total
800 Neoplasms, NOS	18	1	19
801-804 Epithelial neoplasms, NOS	2	2	4
805-808 Squamous cell neoplasms	12	4	16
812-813 Transitional cell carcinomas	230	55	285
814-838 Adenocarcinomas	7	3	10
844-849 Cystic, mucinous and serous neoplasms	0	1	1
Total	269	66	335



Figure 42: Age specific rates- Urinary bladder



Figure 43: ASR, 1985-2010, Urinary bladder

Table 32: Brain - Incidence data 2010

Group	Number	Percentage	ASR	Cum. Rate
Male	132	1.7	1.3	0.13
Female	108	1.2	1.1	0.10
Total	240	1.4	1.2	0.11

ASR: Age standardized rate per 100,000 world population

Cum. Rate- Cumulative Rate (0-74 years) per 100 population

ICD O code and site	Male	Female	Total
C71.0 Cerebrum	4	5	9
C71.1 Frontal lobe	15	8	23
C71.2 Temporal lobe	9	2	11
C71.3 Parietal lobe	11	4	15
C71.4 Occipital lobe	1	2	3
C71.5 Ventricle, NOS	1	1	2
C71.6 Cerebellum, NOS	5	9	14
C71.7 Brain stem	10	9	19
C71.8 Overlapping lesion of brain	10	7	17
C71.9 Brain, NOS	66	61	127
Total	132	108	240

ICD O code and histology	Male	Female	Total
800 Neoplasms, NOS	5	3	8
880 Soft tissue tumours and sarcomas, NOS	0	1	1
906-909 Germ cell neoplasms	0	1	1
912-916 Blood vessel tumours	0	2	2
938-948 Gliomas	126	100	226
959 Malignant lymphomas, NOS or diffuse	1	0	1
967-969 Mature B-cell lymphomas	0	1	1
Total	132	108	240



Figure 44: Age specific rates- Brain



Figure 45: ASR, 1985-2010, Brain

Table 33: Thyroid gland - Incidence data 2010

Group	Number	Percentage	ASR	Cum. Rate
Male	204	2.6	2.0	0.22
Female	832	9.3	7.4	0.69
Total	1036	6.1	4.8	0.46

ASR: Age standardized rate per 100,000 world population

Cum. Rate- Cumulative Rate (0-74 years) per 100 population

ICD O code and site	Male	Female	Total
C73.9 Thyroid gland	204	832	1036
Total	204	832	1036

ICD O code and histology	Male	Female	Total
800 Neoplasms, NOS	6	21	27
801-804 Epithelial neoplasms, NOS	10	23	33
805-808 Squamous cell neoplasms	4	7	11
814-838 Adenocarcinomas	177	764	941
850-854 Ductal and lobular neoplasms	6	11	17
912-916 Blood vessel tumours	0	1	1
959 Malignant lymphomas, NOS or diffuse	0	1	1
967-969 Mature B-cell lymphomas	1	4	5
Total	204	832	1036



Figure 46: Age specific rates- Thyroid gland



Figure 47: ASR, 1985-2010, Thyroid gland

Staging information of common cancers- 2010

Figures, 24, 25 and 26 give the staging information of the three main cancers namely, breast, cervical and oral cancers. Information on staging was available for 1380 (56.6%) of breast cancers, 469 (55.5%) of cervical cancers and 443 (16.7%) of oral cancers. The percentages computed are out of the cancers with staging information.



Figure 48: Stage at diagnosis- Breast cancer



Figure 49: Stage at diagnosis- Cervical cancer



Figure 50: Stage at diagnosis- Oral cancer

Table 34: Basis of diagnosis of cancer patients 2010

Basis of diagnosis		Frequency		Percent
Diagnosed microscopically				
	Histology of primary tumour	14,326	84.45	
	Cytology/ Haematology	1310	7.72	
	Histology of a metastasis	628	3.70	
	Subtotal	**16,264**		**95.88**
Diagnosed non-microscopically				
	Clinical only	27	0.16	
	Clinical Investigation including ultrasound, X-ray, endoscopy etc.	418	2.46	
	Exploratory surgery	07	0.04	
	Laboratory test	11	0.06	
	Subtotal	**463**		**2.73**
Unknown/ Not recorded		**236**		**1.39**
	Total	**16,963**		**100.00**



Figure 51: Basis of diagnosis



Figure 52: Basis of diagnosis by major categories

Table 35: Cancer treatment 2010

Treatment	Frequency	Percentage
Surgery (S)	972	5.7
Radiotherapy (R)	1255	7.4
Chemotherapy (C)	1691	10.0
Hormone (H)	37	0.2
Other -Symptomatic treatment (O)	302	1.8
S + R	1710	10.1
S + C	1303	7.7
S + H	73	0.4
S + O	150	0.9
R + C	1383	8.2
R + H	44	0.3
R + O	278	1.6
C + H	37	0.2
C + O	562	3.3
H + O	9	0.1
S + R + C	1384	8.2
S + R + H	101	0.6
S + R + O	246	1.5
S + C + H	96	0.6
S + C + O	223	1.3
S + H + O	27	0.2
R + C + H	38	0.2
R + C + O	435	2.6
R + H + O	11	0.1
C + H + O	13	0.1
S + R + C + H	571	3.4
S + R + C + O	235	1.4
S + C + H + O	40	0.2
S + R + H + O	25	0.1
R + C + H + O	15	0.1
S + R + C + H + O	150	0.9
Treatment unknown	3547	20.9
Total	16963	100.0



Figure 53: Percentage of patients who received different types of treatment

Table 36: Cancer incidence by geographical area- 2010

Province	District	Male		Female		Total	
		No.	%	No.	%	No.	%
	Not known	1231	15.4	801	8.9	2032	12.0
Central							
	Kandy	655	8.2	835	9.3	1490	8.8
	Matale	191	2.4	170	1.9	361	2.1
	Nuwara Eliya	192	2.4	219	2.4	411	2.4
Eastern							
	Trincomalee	50	0.6	101	1.1	151	0.9
	Baticaloa	133	1.7	173	1.9	306	1.8
	Ampara	123	1.5	165	1.8	288	1.7
Northern							
	Vavuniya	32	0.4	58	0.6	90	0.5
	Mullativu	6	0.1	12	0.1	18	0.1
	Kilinochchi	16	0.2	26	0.3	42	0.2
	Mannar	11	0.1	28	0.3	39	0.2
	Jaffna	149	1.9	207	2.3	356	2.1
North Central							
	Anuradhapura	237	3.0	294	3.3	531	3.1
	Polonnaruwa	131	1.6	123	1.4	254	1.5
North Western							
	Kurunegala	562	7.0	530	5.9	1092	6.4
	Puttalum	187	2.3	214	2.4	401	2.4
Sabaragamuwa							
	Ratnapura	276	3.5	346	3.9	622	3.7
	Kegalle	325	4.1	351	3.9	676	4.0
Southern							
	Galle	515	6.4	592	6.6	1107	6.5
	Matara	317	4.0	379	4.2	696	4.1
	Hambantota	190	2.4	233	2.6	423	2.5
Uva							
	Moneragala	75	0.9	84	0.9	159	0.9
	Badulla	345	4.3	373	4.2	718	4.2
Western							
	Colombo	885	11.1	1192	13.3	2077	12.2
	Gampaha	784	9.8	916	10.2	1700	10.0
	Kalutara	375	4.7	548	6.1	923	5.4
Total		7993	100.0	8970	100.0	16963	100.0

Figure 54: Cancer incidence by districts- 2010

Breast Cancer
(Male and Female)



No. 2440
CR 11.8

Lip, oral Cavity and Pharynx
(Male and Female)



No. 2422
CR 11.7

Cervix



No. 841
CR 8.1

Ovary



No. 680
CR 6.5

Colon and Rectum
(Male and Female)



No. 1083
CR 5.2

Oesophagus
(Male and Female)



No. 1070
CR 5.2

Thyroid Gland
(Male and Female)



No. 1036
CR 5.1

Trachea, Bronchus and Lung
(Male and Female)



No. 1015
CR 4.9

Prostate Gland



Unknown Primary Site (Male and Female)



Figure 55: Male cancer incidence by districts- 2010





Oesophagus
(Male)



No. 574
CR 5.6

Colon and Rectum
(Male)



No. 567
CR 5.5

Prostate
(Male)



No. 480
CR 4.7

Unknown Primary Site
(Male)



No. 436
CR 4.3


Lymphoma
(Male)
Legend
District
0 - 2
2 - 4
4 - 6
6 - 8
No. 419
CR 4.1
Jaffna CR= 2.1 N= 6
Kilinochchi CR= 1.3 N= 1
Mullaitivu CR= 0 N= 0
Vavuniya CR= 0 N= 0
Mannar CR= 0 N= 0
Trincomalee CR= 1.1 N= 2
Batticaloa CR= 2.7 N= 7
Ampara CR= 3.8 N= 12
Monaragala CR= 1.8 N= 4
Polonnaruwa CR= 1.4 N= 3
Anuradhapura CR= 0.7 N= 3
Matale CR= 4.8 N=12
Kurunegala CR= 3.9 N= 30
Puttalam CR= 3.4 N= 13
Kandy CR= 3.3 N= 23
Kegalle CR= 2.8 N= 11
Gampaha CR= 5.2 N= 55
Nuwara Eliya CR= 2.6 N= 10
Badulla CR= 5 N= 22
Ratnapura CR= 2.5 N=14
Colombo CR= 5 N= 65
Kalutara CR= 3.4 N= 19
Hambantota CR= 3.2 N= 9
Matara CR= 3.4 N= 14
Galle CR= 7.6 N=40
Larynx
(Male)
Legend
District
0 - 2
2 - 4
4 - 6
6 - 8
No. 384
CR 3.7
Jaffna CR= 2.4 N= 7
Kilinochchi CR= 1.3 N= 1
Mullaitivu CR= 0 N= 0
Vavuniya CR= 1.2 N= 1
Mannar CR= 0 N= 0
Trincomalee CR= 1.1 N= 2
Batticaloa CR= 1.5 N= 4
Ampara CR= 0.9 N= 3
Monaragala CR= 0.9 N= 2
Polonnaruwa CR= 3.3 N= 7
Anuradhapura CR= 3.8 N= 16
Matale CR=4.8 N=12
Kurunegala CR= 4.3 N=33
Puttalam CR=4.9 N=19
Kandy CR= 4 N= 28
Kegalle CR=4.8 N=19
Gampaha CR= 2.4 N= 25
Nuwara Eliya CR= 0.8 N= 3
Badulla CR= 2.3 N= 10
Ratnapura CR= 2.5 N=14
Colombo CR= 3.5 N=46
Kalutara CR= 5.7 N= 32
Hambantota CR= 1.6 N= 5
Matara CR= 4.7 N=19
Galle CR= 5.1 N=27

Leukaemia (Male)



No. 354
CR 3.5

Bladder (Male)



No. 269
CR 2.6

Figure 56: Female cancer incidence by districts- 2010



Thyroid (Female)



No. 832
CR 8.0

Ovary (Female)



No. 680
CR 6.5

Lip, Oral Cavity and Pharynx (Female)



No. 535
CR 5.1

Colon and Rectum (Female)



No. 516
CR 5.0

Oesophagus
(Female)



No. 496
CR 4.8

Uterus
(Female)



No. 386
CR 3.7

Leukaemia
(Female)



No. 290
CR 2.8

Lymphoma
(Female)



No. 275
CR 2.6

List of References

Cancer Registry, National Cancer Control Programme (2015), Cancer Incidence Data, Sri Lanka, 2009

Cancer Registry, National Cancer Control Programme (2014), Cancer Incidence Data, Sri Lanka, 2008

Cancer Registry, National Cancer Control Programme (2013), Cancer Incidence Data, Sri Lanka, 2007

Cancer Registry, National Cancer Control Programme (2012), Cancer Incidence Data; Sri Lanka 2006

Cancer Registry, National Cancer Control Programme (2009), Cancer Incidence Data; Sri Lanka 2001-2005

Cancer Registry, National Cancer Control Programme (2005), Cancer Incidence Data; Sri Lanka 2000

Cancer Registry, National Cancer Control Programme (2002), Cancer Incidence 1995; Sri Lanka

Cancer Registry, National Cancer Control Programme (1996), Cancer Incidence in Sri Lanka 1990; Sri Lanka

Cancer Registry, National Cancer Control Programme (1990), Cancer Incidence in Sri Lanka 1985; Sri Lanka

Department of Census and Statistics; Estimated midyear population by age and sex, 2000-2010
http://www.statistics.gov.lk/PopHouSat/Mid%20Year%20Population/midyearsex&district.pdf [01 June 2014]

Doll, R., Payne, P., Waterhouse, J.A.H. eds (1966). Cancer Incidence in Five Continents, Vol. I. Union Internationale Contre le Cancer, Geneva.

Fritz, A. Percy, C. Jack, A. Shanmugaratnam, K. Sobin, L. Parkin, D.M. Whelan S. (ed) (2009) International Classification of Diseases of Oncology, 3rd Edition WHO, Geneva

Glossary of statistical terms; http://www-dep.iarc.fr/NORDCAN/english/glossary.htm [01 Dec 2011]
Indian Cancer Society, Parel, Mumbai, India (2009) Cancer Incidence and Mortality in Greater Mumbai, 2005

K.S.Chia, A. Seow, H.P. Lee, K. Shanmugaratnam; (2000) Cancer Incidence in Singapore 1993-1997; Singapore Cancer Registry

Medical Statistics Unit, Ministry of Health, Sri Lanka (2008) Annual Health Statistics, Sri Lanka 2006

National Cancer Centre, Ministry of Health and Welfare, Republic of Korea (2011) Cancer Facts & Figures 2011
Segi, M. (1960) Cancer Mortality for Selected Sites in 24 Countries (1950–57). Department of Public Health, Tohoku University of Medicine, Sendai, Japan

Appendix Statistical Terminology

Population at risk

It is the part of a population which is susceptible to develop a specific cancer. It is defined on the basis of demographic data, such as place of residence, sex, age group, etc. Years of risk duration are counted in person-years

Incidence

Incidence quantifies the number of new cases of disease that develop in a population of individuals at risk during a specified time interval. Usually it is given as per 100,000 population per year.

Mortality

It is usually expressed as a rate. It is a measure of the number of deaths (in general due to a specific cause) in a specific population, per unit time. Mortality rate is typically expressed in units of deaths per 1000 individuals per year.

Crude rate

Data on incidence or mortality are often presented as rates. For a specific tumour and population, a crude rate is calculated simply by dividing the number of new cancers or cancer deaths observed during a given time period by the corresponding number of person years in the population at risk. It is usually expressed as an annual rate per 100,000 persons at risk.

Crude incidence rate

= Total number of cases in the year/ Total midyear population at risk

Crude death rate

= Total number of deaths in the year/ Total midyear population at risk

Age-specific rate

The age-specific rate is calculated simply by dividing the number of new cancers or cancer deaths observed in a given age category during a given time period by the corresponding number of person years in the population at risk in the same age category and time period. The result is usually expressed as an annual rate per 100,000 person-years. In this publication, five-year age categories are used (highest group 75+).

Age –specific incidence rate

= Number of cases in the five-year age group/ population at risk in the corresponding age group

Age –specific death rate

= Number of deaths in the five-year age group/ population at risk in the corresponding age group

ASR (age-standardised rate)

Standardised rates are statistically constructed summary rates that account for the difference between populations. An age-standardised rate (ASR) is a summary measure of the rate that a population would have if it had a standard age structure. Standardisation is necessary when comparing several populations that differ with respect to age because age has such a powerful influence on the risk of cancer. The ASR is a weighted mean of the age-specific rates; the weights are taken from population distribution of the standard population. In this publication 'World Population' was taken as the standard population.

National Cancer Control Programme
555, Elvitigala Mawatha,
Colombo 5
Sri Lanka

ISBN 978-955-0505-84-5